
International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 73

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in *Cumulative List No. 15, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 73

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la *Liste récapitulative No. 15, 2013* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 73

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en *Cumulative List No. 15, 2013* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: Recommended INN	Chemical name or description; Molecular formula; Graphic formula
DCI Recommandée	Nom chimique ou description; Formule brute; Formule développée
DCI Recomendada	Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
abrilumabum # abrilumab	immunoglobulin G2-kappa, anti-[<i>Homo sapiens</i> integrin ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin α4β7, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1)], <i>Homo sapiens</i> monoclonal antibody; gamma2 heavy chain (1-444) [<i>Homo sapiens</i> VH(IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide
abrilumab	immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> intégrine ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine α4β7, récepteur d'adressage spécifique des plaques de Peyer, LPAM-1)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma2 (1-444) [<i>Homo sapiens</i> (IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère(220-220":221-221":224-224":227-227")-tétrakisdisulfure
abrilumab	inmunoglobulina G2-kappa, anti-[<i>Homo sapiens</i> integrina ITGA4_ITGB7 (integrina alfa4 (CD49d)_beta7, integrina α4β7, molécula de adhesión específica de linfocitos de las placas de Peyer, LPAM-1)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma2 (1-444) [<i>Homo sapiens</i> (IGHV1-24*01 (94.90%) -(IGHD)-IGHJ5*02) [8.8.11] (1-118) - IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero(220-220":221-221":224-224":227-227")-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKVSGYTLS DLSIHVVVQA PGKGLEWMGG 50
 FDPQDGETIY AQKFQGRVTM TETDSTDTAY MELSSLKSED TAVYYCATGS 100
 SSSWFDPMGQ GTLTVTSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
 CNVDHKPSNT KVDKTVKRC CVECPCPCAP PVAGPSVFLF PPKPKDTLMI 250
 SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNATKPRE EQFNSTFRVV 300
 SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
 SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPLDSDGS 400
 FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS VSASVGRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG 50
 ASNLESGVPS RFGSGSGSDT FTLTISLQPE EDFANYCQQ ANSFPTWFGQ 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKKH VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 258-318 364-422
 22"-96" 145"-201" 258"-318" 364"-422"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 132-214' 132"-214"
 Inter-H-H (h 4, h 5, h 8, h 11) 220-220" 221-221" 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 294, 294"

acorafloxacinum

acorafloxacin


7-[(3*E*)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-
 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-
 1,4-dihydroquinoline-3-carboxylic acid

acorafloxacin

acide 7-[(3*E*)-3-(2-amino-1-fluoroéthylidène)pipéridin-1-yl]-
 1-cyclopropyl-6-fluoro-8-méthoxy-4-oxo-
 1,4-dihydroquinoléine-3-carboxylique

acorafloxacin

ácido 7-[(3*E*)-3-(2-amino-1-fluoroetilideno)piperidin-1-il]-
 1-ciclopropil-6-fluoro-8-metoxi-4-oxo-1,4-dihidroquinolina-
 3-carboxílico

C₂₁H₂₃F₂N₃O₄**acumapimodum**

acumapimod



3-[5-amino-4-(3-cyanobenzoyl)-1*H*-pyrazol-1-yl]-
N-cyclopropyl-4-methylbenzamide

acumapimod

3-[5-amino-4-(3-cyanobenzoyl)-1*H*-pyrazol-1-yl]-
N-cyclopropyl-4-méthylbenzamide

acumapimod

3-[5-amino-4-(3-cianobenzoil)-1*H*-pirazol-1-il]-*N*-ciclopropil-
 4-metilbenzamida



albenatidum #
albenatide

S^{3,34} -{1-[(23S)-23-[[exendin-4 *Heloderma suspectum* precursor-(48-86)-peptidyl (exenatidyl)]amino]-3,12,24-trioxo-7,10-dioxo-4,13,18,25-tetraazapentacosyl]-2,5-dioxopyrrolidin-3-yl}human serum albumin. Peptide is synthetic, and human serum albumin is produced in *Saccharomyces cerevisiae*.

albénatide

S^{3,34} -{1-[(23S)-23-[[précurseur de l'exendin-4 de *Heloderma suspectum*-(48-86)-peptidyl (exénatidyl)]amino]-3,12,24-trioxo-7,10-dioxo-4,13,18,25-tétraazapentacosyl]-2,5-dioxopyrrolidin-3-yl}albumine sérique humaine. Le peptide est synthétique et l'albumine sérique humaine est produite par *Saccharomyces cerevisiae*.

albenatida


S^{3,34} -{1-[(23S)-23-[[precursor de la exendina-4 de *Heloderma suspectum*-(48-86)-peptidil (exenatidil)]amino]-3,12,24-trioxo-7,10-dioxo-4,13,18,25-tetraazapentacosil]-2,5-dioxopirrolidin-3-il}albúmina sérica humana. El péptido es sintético y la albúmina sérica humana la produce el *Saccharomyces cerevisiae*.

Human Albumin / Albumine humaine / Albumina humana
 DAHKSEVAHR FKDLGEENFK ALVLIIFAQY LQQCFPEDHV KLVNEVTEFA 50
 KTCVADESAR NCDKSLHTLF GDKLCTVATL RETYGMADAC CAKQEPERNE 100
 CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
 APELLFFAKR YKAAFTCECCQ AADKAACLLP KLDELRLDEGK ASSAKQRLKC 200
 ASLKQFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTCCCHGDL 250
 LECADDRADL AKYICENQDS ISSKLKECC KPLLEKSHCI AEVENDEMPA 300
 DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLRLA 350
 KTYETTLKCK CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
 YKFNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCKKH PEAKRMPCAE 450
 DYLSVVLNQL CVLHEKTPVS DRVTCKCTES LVNRRPCFSA LEVDETYVPK 500
 EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
 FAAFVEKCKC ADDKETCFAE EGKKLVAASQ AALGL 585

Exenatidyl / Exénatidyl / Exenatidil
 HGEGTFTSDL SKQMEEEAVR LFIEWLKNKG PSSGAPPPS- 39

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279 278-289
 316-361 360-369 392-438 437-448 461-477 476-487 514-559 558-567

Modified residues / Résidus modifiés / Restos modificados



asvasiranum

asvasiran

small interfering ARN (siRNA) inhibitor of human Respiratory Syncytial Virus replication;
 duplex of guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine and thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidine

asvasiran

petit ARN interférant (siRNA) inhibiteur de la réplication du virus respiratoire syncytial humain;
 duplex de guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine et de thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidine

asvasirán

ARN pequeño de interferencia (ARNip) (siRNA) inhibidor de la replicación del virus respiratorio sincitial humano;
 duplex de guanilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-timidina y de timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidina

C₄₀₁H₅₀₀N₁₅₀O₂₉₀P₄₀

[(3'5')-G-G-C-U-C-U-U-A-G-C-A-A-A-G-U-C-A-A-G-dT-dT]

.

[(5'3')-dT-dT-C-C-G-A-G-A-A-U-C-G-U-U-U-C-A-G-U-U-C]

azeliragonum


azeliragon

3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1*H*-imidazol-4-yl}phenoxy)-*N,N*-diethylpropan-1-amine

azéliragon

3-(4-{2-butyl-1-[4-(4-chlorophénoxy)phényl]-1*H*-imidazol-4-yl}phénoxy)-*N,N*-diéthylpropan-1-amine

azeliragón

3-(4-{2-butyl-1-[4-(4-clorofenoxi)fenil]-1*H*-imidazol-4-il}fenoxi)-*N,N*-dietilpropan-1-amina $C_{32}H_{38}ClN_3O_2$ **basmisaniilum**


basmisaniil

(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)(6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl)methanone

basmisaniil

(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)(6-[[3-(4-fluorophényl)-5-méthyl-1,2-oxazol-4-yl]méthoxy]pyridin-3-yl)méthanone

basmisaniil

(1,1-dioxo-1λ⁶-tiomorfolin-4-il)(6-[[3-(4-fluorofenil)-5-metil-1,2-oxazol-4-il]metoxi]piridin-3-il)metanona $C_{21}H_{20}FN_3O_3S$ **beclabuvirum**

beclabuvir



(4*bS*,5*aR*)-12-cyclohexyl-*N*-(dimethylsulfamoyl)-3-methoxy-5a-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4*b*,5,5*a*,6-tetrahydrocyclopropa[*d*]indolo[2,1-*a*][2]benzazepine-9-carboxamide

béclabuvir

(4*bS*,5*aR*)-12-cyclohexyl-*N*-(diméthylsulfamoyl)-3-méthoxy-5a-[(3-méthyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-4*b*,5,5*a*,6-tétrahydrocyclopropa[*d*]indolo[2,1-*a*][2]benzazépine-9-carboxamide

beclabuvir

(4*bS*,5*aR*)-12-ciclohexil-*N*-(dimetilsulfamoil)-3-metoxi-5a-[(3-metil-3,8-diazabíciclo[3.2.1]oct-8-il)carbonil]-4*b*,5,5*a*,6-tetrahidrociclopropa[*d*]indolo[2,1-*a*][2]benzazepina-9-carboxamida



begelomabum #
begelomab

immunoglobulin G2b-kappa, anti-[*Homo sapiens* DPP4(dipeptidyl-peptidase 4, dipeptidylpeptidase IV, adenosine deaminase complexing protein 2, ADCP2, TP103, T cell activation antigen CD26, CD26)], *Mus musculus* monoclonal antibody; gamma2b heavy chain (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), hinge (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimer (229-229":232-232":235-235":238-238")-tetrakisdisulfide

bégélomab

immunoglobuline G2b-kappa, anti-[*Homo sapiens* DPP4 (dipeptidyl-peptidase 4, dipeptidylpeptidase IV, protéine 2 complexant l'adénosine désaminase, ADCP2, TP103, antigène CD26 d'activation des cellules T, CD26)], *Mus musculus* anticorps monoclonal; chaîne lourde gamma2b (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), charnière (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dimère (229-229":232-232":235-235":238-238")-tétrakisdisulfure

begelomab

inmunoglobulina G2b-kappa, anti-[*Homo sapiens* DPP4 (dipeptidil-peptidasa 4, dipeptidilpeptidasa IV, proteína 2 complejante de la adenosina desaminasa, ADCP2, TP103, antígeno CD26 de activación de las células T, CD26)], anticuerpo monoclonal de *Mus musculus*; cadena pesada gamma2b (1-456) [*Mus musculus* VH (IGHV1-85*01 (88.80%) -(IGHD)-IGHJ1*01) [8.8.13] (1-120) -IGHG2B*02 (CH1 (121-217), bisagra (218-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (121-456)], (135-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-57*01 (98.90%) -IGKJ1*01) [5.3.9] (1'-106') -IGKC*01 (107'-213')]; dímero (229-229":232-232":235-235":238-238")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQSGAE	LVPKASVKL	SKKASGYTF	SYDINWVRQR	PEQGLEWIGW	50
IFPGDGS	NEKFKGKATL	TTDKSSSTAY	MLSLRLTSED	SAVYFCARMT	100
VVGGYFDVW	GAGTTVTVSS	AKTTPPSVYP	LAPGCGDTTG	SSVTLGCLVK	150
GYFPESVTVT	WNSGSLSSSV	HTFPALLQSG	LYTMSSSVTV	PSSTWPSQTV	200
TCSVAHPASS	TTVDKKLEPS	GPISTINPCP	PCKECHKCPA	PNLEGGPSVF	250
IFPPNIKDV	LISLTPKVT	VVVDVSEDDP	DVQISWFVNN	VEVHTAQQT	300
HREDYNSTIR	VVSTLPIQH	DWMSGKEFK	KVNNKDLPS	IERTISKIKG	350
LVRAPQVYIL	PPPAEQLSRK	DVSLTCLVVG	FNPGLDISVEW	TSNGHTEENY	400
KDTAPVLDS	GSYFIYSKLN	MKTSKWEKTD	SFSCNVRHEG	LKNYYLKKTI	450
SRSPGK					456

Light chain / Chaîne légère / Cadena ligera

QIVLTQSPAI	MSASPGKVT	ITCSASSSVS	YMNWFQKPG	TSPKLWIYST	50
SNLASGVPAR	FSGSGSGTSY	SLTISRMEAE	DAATYYCQQR	SSYPNTFGGG	100
TKLEIKRADA	APTVSIFPPS	SEQLTSGGAS	VVCFLNNFYP	KDINVKKID	150
GSEQRQGNL	SWTDQDSKDS	TYSMSSTLT	TKDEYERHNS	YTCEATHKTS	200
TSPIVKSFNR	NEC				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22"-96"	147"-202"	270"-330"	376"-434"
	22"-96"	147"-202"	270"-330"	376"-434"

Intra-L (C23-C104)	23"-87"	133"-193"
	23"-87"	133"-193"

Inter-H-L (CH1 11-CL 126)	135"-213"	135"-213"
---------------------------	-----------	-----------

Inter-H-H (h 12, h 15, h 18, h 21)	229"-229"	232"-232"	235"-235"	238"-238"
------------------------------------	-----------	-----------	-----------	-----------

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
306, 306"

benzhydrocodonum


benzhydrocodone

4,5 α -epoxy-3-methoxy-17-methyl-6,7-didehydromorphinan-6-yl benzoate

benzhydrocodone

benzoate de 4,5 α -époxy-3-méthoxy-17-méthyl-6,7-didéhydromorphinan-6-yle

benzhidrocodona

benzoato de 4,5 α -epoxi-17-metil-3-metoxi-6,7-dideshidromorfinan-6-iloC₂₅H₂₅NO₄**bradaniclinum**

bradanicline



N-[(2*S*,3*R*)-2-[(pyridin-3-yl)methyl]-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide

bradanicline

N-[(2*S*,3*R*)-2-(pyridin-3-ylméthyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofurane-2-carboxamide

bradaniclina

N-[(2*S*,3*R*)-2-(piridin-3-ilmetil)-1-azabicio[2.2.2]oct-3-il]-1-benzofurano-2-carboxamida

**briciclibum**

briciclib


2-methoxy-5-((*E*)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonylmethylphenyl dihydrogen phosphate

briciclib

dihydrogénophosphate de 2-méthoxy-5-([2-(2,4,6-triméthoxyphényl)éthényl]sulfonyl)méthylphényl

briciclib

dihidrógenofosfato de 2-metoxi-5-([2-(2,4,6-trimetoxifenil)etenil]sulfonil)metilfenilo

**brontictuzumabum #**

brontictuzumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* NOTCH1 (Notch 1, Translocation-associated notch-1, TAN-1, TAN1)], humanized monoclonal antibody; gamma2 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), hinge (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfide with lambda light chain (1'-215') [humanized V-LAMBDA (*Homo sapiens* IGLV7-46*01 (83.20%) -IGLJ2*01 [9.3.9] (1'-109') -*Homo sapiens* IGLC7*01 (110'-215'))]; dimer (223-223'':224-224'':227-227'':230-230'')-tetrakisdisulfide

brontictuzumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* NOTCH1 (Notch 1, notch-1 associé aux translocations, TAN-1, TAN1)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-447) [VH humanisé (*Homo sapiens* IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116)) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfure avec la chaîne légère lambda (1'-215') [V-LAMBDA humanisé (*Homo sapiens* IGLV7-46*01 (83.20%) -IGLJ2*01 [9.3.9] (1'-109') -*Homo sapiens* IGLC7*01 (110'-215'))]; dimère (223-223'':224-224'':227-227'':230-230'')-tétrakisdisulfure

brontictuzumab

inmunoglobulina G2-lambda, anti-[NOTCH1 de *Homo sapiens* (Notch 1, notch-1 asociado a las translocaciones, TAN-1, TAN1)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-447) [VH humanizado (*Homo sapiens*IGHV1-24*01 (80.40%) -(IGHD)-IGHJ4*01 L123>T (116))] [8.8.14] (1-121) -*Homo sapiens*IGHG2*01 (CH1 (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera lambda (1'-215') [V-LAMBDA humanizada (*Homo sapiens*IGLV7-46*01 (83.20%) -IGLJ2*01] [9.3.9] (1'-109') -*Homo sapiens*IGLC7*01 (110'-215')]; dímero (223-223":224-224":227-227":230-230")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKI SKVSGYTLR GYIEWVRQA PGKGLEWIGQ 50
ILPGTGRNTY NEKFKGRVTM TADTSTDYAY MELSSLSRSED TAVYICARFD 100
GNYGYYAMDY WQGGTTVTVS SASTKGPSVF PLAPCSRSTS ESTALGCLV 150
KDYFPEPPTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDPKPK SNTKVDKTVK RKCCVECPFC PAPPVAGPSV FLFPKPKDPT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTIVH QDWLNGKEYK CKVSNKGLPA PIEKTIKTKK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPMPLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNYHTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera

QAVVTQEPST TVSPGGTITL TCRSSTGAVT TSNYANWFQQ KPGQAPRTLI 50
GGTNNRAPGV PARFSGSLLG GKAALTLSGA QPEDEAEYIC ALWYSNHWVF 100
GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLVS DFYPGAIVTA 150
WKADGSPVKV GVEITPKPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCRVT 200
EGSTVEKTVA PAECSS 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 261-321 367-425
22"-96" 148"-204" 261"-321" 367"-425"
Intra-L (C23-C104) 22'-90' 137'-196'
22'''-90''' 137'''-196'''

Inter-H-L (CH1 10-CL 126) 135-214' 135"-214"
Inter-H-H (h 4, h 5, h 8, h 11) 223-223" 224-224" 227-227" 230-230"
Possible other H-L and H-H crosslinks
Inter-H-L 223-214' 223"-214"
Inter-H-H 135-224" 135"-224" 227-227" 230-230"
Possible other H-L and H-H crosslinks
Inter-H-L 135-214' 223"-214"
Inter-H-H 223-135" 224-224" 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
297, 297"

butylphthalidum


butylphthalide

rac-3-butyl-2-benzofuran-1(3*H*)-one

butylphthalide

rac-3-butyl-2-benzofuran-1(3*H*)-one

butilftalida

rac-3-butil-2-benzofuran-1(3*H*)-onaC₁₂H₁₄O₂

and enantiomer
et énantiomère
y enantiómero

cabotegravirum


cabotegravir

(3*S*,11*aR*)-*N*-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11*a*-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide

cabotégavir (3*S*,11*aR*)-*N*-[(2,4-difluorophényl)méthyl]-6-hydroxy-3-méthyl-5,7-dioxo-2,3,5,7,11,11*a*-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide

cabotegravir (3*S*,11*aR*)-*N*-[(2,4-difluorofenil)metil]-6-hidroxi-3-metil-5,7-dioxo-2,3,5,7,11,11*a*-hexahydrooxazolo[3,2-*a*]pirido[1,2-*d*]pirazina-8-carboxamida

C₁₉H₁₇F₂N₃O₅




capmatinibum
capmatinib

2-fluoro-*N*-methyl-4-{7-[(quinolin-6-yl)méthyl]imidazo[1,2-*b*][1,2,4]triazin-2-yl}benzamide

capmatinib 2-fluoro-*N*-méthyl-4-{7-[(quinoléin-6-yl)méthyl]imidazo[1,2-*b*][1,2,4]triazin-2-yl}benzamide


capmatinib 2-fluoro-*N*-metil-4-{7-[(quinolein-6-il)metil]imidazo[1,2-*b*][1,2,4]triazin-2-il}benzamida

C₂₃H₁₇FN₆O




cefilavancinum
cefilavancin

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-({3-[(3*S*,6*R*,7*R*,22*R*,23*S*,26*S*,30*aS*_a,36*R*,38*aR*)-3-(2-amino-2-oxoethyl)-44-[[2-*O*-(3-amino-2,3,6-trideoxy-3-*C*-methyl- α -*L*-lyxo-hexopyranosyl)- β -*D*-glucopyranosyl]oxy]-10,19-dichloro-7,22,28,30,32-pentahydroxy-6-[(*N*-methyl-*D*-leucyl)amino]-2,5,24,38,39-pentaoso-2,3,4,5,6,7,23,24,25,26,36,37,38,38*a*-tetradecahydro-1*H*,22*H*-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno[1,6,9]oxadiazacyclohexadecino[4,5-*m*][10,2,16]benzoxadiazacyclotetracosine-26-carboxamido]propoxy)imino)acetamido]-8-oxo-3-[(pyridin-1-ium-1-yl)méthyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

cerdulatinib	4-(cyclopropylamino)-2-({4-[4-(éthanesulfonyl)pipérazin-1-yl]phényl}amino)pyrimidine-5-carboxamide
cerdulatinib	4-(ciclopropilamino)-2-({4-[4-(etanosulfonyl)piperazin-1-il]fenil}amino)pirimidina-5-carboxamida
	$C_{20}H_{27}N_7O_3S$
	
cerliponasum alfa # cerliponase alfa	immature human tripeptidyl-peptidase 1 (cell growth-inhibiting gene 1 protein, lysosomal pepstatin-insensitive protease, TPP-1, EC 3.4.14.9), 544 residues protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
cerliponase alfa	tripeptidyl-peptidase 1 humaine immature (protéine du gène 1 inhibitrice du développement cellulaire, protéase lysosomiale non-contrôlée par la pepstatine, TPP-1, EC 3.4.14.9), protéine de 544 résidus, produite par des cellules ovariennes de hamster chinois, forme glycosylée alfa
cerliponasa alfa	tripeptidil-peptidasa 1 humana inmadura (proteína del gen 1 inhibidora del desarrollo celular, proteasa lisosomial no controlada por la pepstatina, TPP-1, EC 3.4.14.9), proteína de 544 restos, producida por células ováricas de hamster chino, forma glicosilada alfa
	$C_{2657}H_{4042}N_{734}O_{793}S_{11}$
	Sequence / Séquence / Secuencia SISPEPDQRR TLPPGWVSLG RADPEEELS L TFALRQQNVE RLSELVQAVS 50 DFSSPQYGRY LTLENVADLV RPSPLTLHTV QRWLLAAGAQ KCHSVITQDF 100 LTCWLSIRQA ELLLPFGAEFH HYVGGPTETH VVRSPHPYQL PQALAPHVDF 150 VGGLHREFPT SLLRQREBQ VTGTVGLHLG VTPSVIRKRY NLTSQDVGS 200 TSNNSOACQA FLEQYFHSD LAQFMRLFG NFAHQASVAR VVGQGRGRA 250 GTEASLDVQY LMSAGANIST WVTSSPGRHE QGEPLQWLM LLSNESALPH 300 VHTVSYGDDE DSLSSAIIQR VNTELMKAA RGLTLLFASG DSGAGCWSVS 350 GRHQFRPTFP ASSPYVTIVG GTSFQEPFLI TNEIVDYISG GGFNSVFRP 400 SYQEEAVTKF LSSSPHLPPS SYFNASGRAY PDVAALSDGY WVVSNRVP 450 WVSGTSASTP VFGGILSLIN EHRILSGRPP LGFLNPRLYQ QHGAGLFDVT 500 RGCHECLDE EVEGQGFCSG PGWDPVTGWG TPNFPALLKT LLNP 544
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 92-103 346-507 503-518
	Glycosylation sites (N)/ Sites de glycosylation (N) / Posiciones de glicosilación (N) Asn-191 Asn-203 Asn-267 Asn-294 Asn-424
dagrocoratum dagrocorat	(4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide
dagrocorat	(4bS,7R,8aR)-4b-benzyl-7-hydroxy-N-(2-méthylpyridin-3-yl)-7-(trifluorométhyl)-4b,5,6,7,8,8a,9,10-octahydrophénanthrène-2-carboxamide

dagrocorat

(4b*S*,7*R*,8a*R*)-4b-bencil-7-hidroxi-*N*-(2-metilpiridin-3-il)-7-(trifluorometil)-4b,5,6,7,8,8a,9,10-octahidrofenantreno-2-carboxamida

 $C_{29}H_{29}F_3N_2O_2$


dalazatidum
dalazatide

a 37-residue, synthetic peptide derivative of the *Stichodactyla* toxin:
O-phosphono-L-tyrosyl-2-[2-(2-aminoethoxy)ethoxy]acetyl[potassium channel toxin kappa-stichotoxin-Shela *Stoichactis helianthus* (Caribbean sea anemone)] peptidamide

dalazatide

peptide synthétique de 37 acides aminés dérivé de la toxine extraite de *Stichodactyla*:
O-phosphono-L-tyrosyl-2-[2-(2-aminoéthoxy)éthoxy]acétyl[toxine kappa du canal potassique-stichotoxine-Shela *Stoichactis helianthus* (anémone de mer des Antilles)] peptidamide

dalazatida

péptido sintético de 37 aminoácidos derivado de la toxina extraída de *Stichodactyla*:
O-fosfono-L-tirosil-2-[2-(2-aminoetoxi)etoxi]acetil[toxina kappa del canal de potasio-stichotoxina-Shela *Stoichactis helianthus* (anémona del Mar de las Antillas)] peptidamida

 $C_{184}H_{296}N_{57}O_{55}PS_7$


Sequence / Séquence / Secuencia

YXRSCIDTIP KSRCTAFQCK HSMKYRLSFC RKTGCTC 37

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
5-37 14-30 19-34

Modified residues / Résidus modifiés / Restos modificados

X (2) 2-[2-(2-aminoethoxy)ethoxy]acetic acid



dapaconazolium
dapaconazole



1-[*rac*-2-(2,4-dichlorophenyl)-2-[[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1*H*-imidazole

dapaconazole

1-[*rac*-2-(2,4-dichlorophényl)-2-[[4-(trifluorométhyl)phényl]méthoxy]éthyl]-1*H*-imidazole

dapaconazol

1-[*rac*-2-(2,4-diclorofenil)-2-[[4-(trifluorometil)fenil]metoxi]etil]-1*H*-imidazol



defactinibum
defactinib



N-methyl-4-({4-({[3-(*N*-methylmethanesulfonamido)pyrazin-2-yl]methyl)amino}-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide

défactinib

N-méthyl-4-({4-({[3-(*N*-méthylméthanesulfonamido)pyrazin-2-yl]méthyl)amino}-5-(trifluorométhyl)pyrimidin-2-yl}amino)benzamide

defactinib

N-metil-4-({4-({[3-(*N*-metilmetanesulfonamido)pirazin-2-il]metil}amino)-5-(trifluorometil)pirimidin-2-il}amino)benzamida



denintuzumabum mafodotinum #
denintuzumab mafodotin

immunoglobulin G1-kappa auristatin F conjugate, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], humanized monoclonal antibody; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens*IGHG1*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens*IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens*IGKC*01 (107'-213')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker

For the *mafodotin* part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

dénintuzumab mafodotiné

immunoglobuline G1-kappa conjuguée à l'auristatine F, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable

Pour la partie *mafodotiné*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

denintuzumab mafodotina

immunoglobulina G1-kappa conjugada con la auristatina F, anti-[CD19 de *Homo sapiens* (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV4-31*02 (84.80%) -(IGHD)-IGHJ4*01) [10.7.12] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*02) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (229-229":232-232")-bisdisulfuro; conjugado, en 4 restos cisteinil por término medio, con monometilauristatina F (MMAF), mediante un conector maleimidocaproyl (mc) no escindible

La fracción *mafodotina*, pueden encontrarla en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG LVKPSQTLST TCTVSGGSIS TSGMGVGWIR QHPGKGLEWI 50
GIHWDDDKR YNPALKSRVT ISVDTSKNQF SLKLSSVTAA DTAVVYCARM 100
ELWSYFDYW GQGLTVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VFSSSLGTQT 200
YICNVNKKFS NTKVDKVEE KSCDKTHTCP PCPAPELLGG PSVFLFPPKE 250
KDELMSRTP EVTCVVVDVS HEDPEVKENI YVGVVEVHNA KTKPREEQYN 300
STYRVVSVLT VLGQDWLNGK EYCKRVSNKA LPAPIEKTIK KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LDSGGSFFLY SKLTVDKSRW QGQNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCSASSSVS YMHVYQQKPG QAPRLLIYDT 50
SKLASGIPAR FSGSGSGTDF TLTISSELEP DVAVYCFQG SVYPFTFGQG 100
TKLEIKRTVA APSVFIFFPS DEQLKSGTAS VVCLLNNFYF REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLT SKADYERKRV YACEVTHQGL 200
SSPVTKSFNR GEC 213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-97 147-203 264-324 370-428
22"-97" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23'-87' 133'-193'
23"-87" 133"-193"

Inter-H-L (h 5-CL 126) * 223-213' 223"-213"
Inter-H-H (h 11, h 14) * 229-229" 232-232"

*Two inter-chain disulfide bridges are not present on average, the antibody being conjugated to an average of 4 drug linkers, each bound to a cysteinyl via a thioether bond

*Deux des ponts disulfure inter-chaînes ne sont pas présents en moyenne, l'anticorps étant conjugué à une moyenne de 4 linker-principe actif, chacun via une liaison thioéther.

*Faltan dos puentes disulfuro intercatenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 4 conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

dianhydrogalactitol


dianhydrogalactitol

meso-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-yl]-2-[(2*S*)-oxiran-2-yl]ethane-1,2-diol

dianhydrogalactitol

*més*o-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-yl]-2-[(2*S*)-oxiran-2-yl]éthane-1,2-diol

dianhidrogalactitol

meso-(1*R*,2*S*)-1-[(2*R*)-oxiran-2-il]-2-[(2*S*)-oxiran-2-il]etano-1,2-diolC₆H₁₀O₄**diclofenaci etalhyaluronas**

diclofenac etalhyaluronate


hyaluronic acid partly amidified with 2-(2-{[(2,6-dichlorophenyl)amino]phenyl}acetyloxy)ethanamine

étalhyaluronate de diclofénac

acide hyaluronique partiellement amidifié par la 2-(2-{[(2,6-dichlorophényl)amino]phényl}acétyloxy)éthanamine

etalhialuronato de diclofenaco

ácido hialurónico parcialmente amidificado por 2-(2-{[(2,6-diclorofenil)amino]fenil}acetiloxi)etanamina

[(C₃₀H₃₅Cl₂N₃O₁₂)_a(C₁₄H₂₁NO₁₁)_b]_nH₂O**diridavumabum #**

diridavumab

immunoglobulin G1-lambda2, anti-[influenza A virus hemagglutinin HA2 subunit (H1, H2, H5, H6, H8 and H9 subtypes)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14](1-121) -IGHG1*03 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450)(122-450)], (224-216')-disulfide with lambda2 light chain(1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (230-230":233-233")-bisdisulfide

diridavumab

immunoglobuline G1-lambda2, anti-[sous-unité HA2 de l'hémagglutinine du virus de la grippe A (sous-types H1, H2, H5, H6, H8 et H9)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14] (1-121) -IGHG1*03 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450)(122-450)), (224-216')-disulfure avec la chaîne légère lambda2 (1'-217')] [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimère (230-230":233-233")-bisdisulfure

diridavumab

inmunoglobulina G1-lambda2, anti-[subunidad HA2 de la hemaglutinina del virus de la gripe A (sub-tipos H1, H2, H5, H6, H8 y H9)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (84.70%) -(IGHD)-IGHJ6*03) [8.8.14] (1-121) -IGHG1*03 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS K2>del (450) (122-450)), (224-216')-disulfuro con la cadena ligera lambda2 (1'-217')] [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (92.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
EVQLVESGAE VKKPGSSVKV SCKASGGPFR SYAISWVRQA PGQGPWMGG 50
IIPFGFTTKY APKFGGRVTI TADDFAGTVY MELSSLRSED TAMYCAKHM 100
GYQVRETM DV WKGKTTTVTS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSLVV TVPSSSLGTQ 200
TYICNVNHKPT SNRKVDKRVF PKSCDKTHFT PCFAPPELLG GPSVLEFPFK 250
PKDTLMISRT PEVTCVVYDV SHEDEPKVHN WIVDGEVEHN AKTKQEPPEQ 300
NSTYRVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFPYPSD IAVENESNGQ PENNYKTTTP 400
VLDSDGSPFL YSKLTVDKSR WQGGNVFSCS VMHEALHNHY TQKSLSLSPG 450

Light chain / Chaîne légère / Cadena ligera
QSVLTQPPSV SAAPGQKVTI SCSGSSNIG NDVSWYQQL PGTAPKLLIY 50
DNNKRPSPGIP DRFSGSGSGT SATLGITGLQ TGDEANYCA TWDRRPTAYV 100
VFGGGTKLTV LGQPKAAPSV TLFPSSSEEL QANKATLVCL ISDFYPGAVT 150
VAMKADSSPV KAGVETTPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 22-89" 139-198"
22"-89" 139"-198"
Inter-H-L (h 5-CL 126) 224-216" 224"-216"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"

Other post-translational modifications
Autres modifications post-traduccionnelles
Otras modificaciones post-traduccionales
Lacking H chain C-terminal lysine (CHS K2>del)

eflapeggrastimum #
eflapeggrastim

human granulocyte colony-stimulating factor and human IgG4 Fc dimer linked together with polyethylene glycol derivative, produced in *Escherichia coli*:
N^{a,1}, N^{1,9}-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] des-(1-L-alanine,37-39)-[18-L-serine(C>S),69-L-serine(P>S)]human granulocyte colony-stimulating factor (G-CSF, pluripoiectin) (1-174)-peptide and des-(1-8)-human immunoglobulin G4 Fc fragment (IGHG4*01 H-CH2-CH3) (9'-229')-peptide dimer (11'-11")-disulfide

éflapégrastim

le facteur de stimulation de colonies de granulocytes humain et le dimère du fragment Fc de l'IgG4 humaine, produits par *Escherichia coli*, reliés par un radical substituant dérivé du polyéthylèneglycol:
 $N^{0.1}, N^{1.9}$ -[ω -(oxypropane-1,3-diyl)- α -(propane-1,3-diyl)poly(oxyethylene)] des-(1-L-alanine,37-39)-[18-L-sérine(C>S), 69-L-sérine(P>S)]facteur de stimulation de colonies de granulocytes humain (G-CSF, pluripoiétine) (1-174)-peptide et (11'-11'')-disulfure du dimère de des-(1-8)-fragment Fc de l'immunoglobuline G4 humaine (IGHG4*01 H-CH2-CH3) (9'-229')-peptide

eflapegrastim

producto de la unión, mediante un radical derivado del polietilenglicol, del factor estimulante de colonias de granulocitos humano y el dímero del fragmento Fc de la IgG4 humana, producidos por *Escherichia coli*.
 $N^{0.1}, N^{1.9}$ -[ω -(oxipropano-1,3-diil)- α -(propano-1,3-diil)poli(oxietileno)] des-(1-L-alanina,37-39)-[18-L-serina(C>S),69-L-serina(P>S)]factor estimulante de colonias de granulocitos humano (G-CSF, pluripoyetina) (1-174)-péptido y (11'-11'')-disulfuro del dímero de des-(1-8)-fragmento Fc de la inmunoglobulina G4 humana (IGHG4*01 H-CH2-CH3) (9'-229')-péptido

Human G-CSF derivative sequence / Séquence dérivée du G-CSF humain / Secuencia derivada de G-CSF humano

TFLGPASSLP QSFLLKSLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
 GHSIGIPWAP LSSCSSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
 PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
 VLVASHLQSF LEVSYRVLRLH LAQP 174

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4


PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVDSQ 50'
 EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLT V LQDQDLNGKE 100'
 YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
 VKGFYPSDIA VEWESNGQPE NNYKTPPV L DSDGSFFLYS RLTVDKSRWQ 200'
 EGNVFSQSV M HEALHNHYTQ KSLSLSLGK 229'

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4

PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVDSQ 50''
 EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLT V LQDQDLNGKE 100''
 YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
 VKGFYPSDIA VEWESNGQPE NNYKTPPV L DSDGSFFLYS RLTVDKSRWQ 200''
 EGNVFSQSV M HEALHNHYTQ KSLSLSLGK 229''

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 11'-11'' 36-42 43'-103' 43''-103'' 64-74 149'-207' 149''-207''

Modified residues / Résidus modifiés / Restos modificados



efmorotocogum alfa #
 efmorotocog alfa

recombinant DNA derived (1-742)-(1637-2332)-human blood coagulation factor VIII fusion protein with immunoglobulin G1 Fc domain fragment, produced in HEK293H cells, glycoform alfa:
 des-(743-1636)-human blood coagulation factor VIII (antihemophilic factor, procoagulant component) fusion protein with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-6'':1447-9')-bisdisulfide with human immunoglobulin G1 Fc fragment (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

efmoroctocog alfa

(1-742)-(1637-2332)-facteur VIII de coagulation humain protéine de fusion avec le fragment Fc de l'immunoglobuline G1, produite dans les cellules HEK293H à partir d'ADN recombinant, forme glycosylée alfa: dès-(743-1636)-facteur VIII de coagulation humain (facteur antihémostatique, composé procoagulant) protéine de fusion avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide (1444-6':1447-9')-bisdisulfure avec le fragment Fc de l'immunoglobuline G1 humaine (IGHG1*01 H-CH2-CH3)-(6-231)-peptide

efmoroctocog alfa

(1-742)-(1637-2332)-factor VIII de coagulación humano proteína de fusión con el fragmento Fc de la inmunoglobulina G1, producida en las células HEK293H a partir de ADN recombinante, forma glicosilada alfa: des-(743-1636)-factor VIII de coagulación humano (factor antihemofílico, componente procoagulante) proteína de fusión con el fragmento Fc de la inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido (1444-6':1447-9')-bisdisulfuro con el fragmento Fc de la inmunoglobulina G1 humana (IGHG1*01 H-CH2-CH3)-(6-231)-péptido

Fusion protein / Protéine de fusion / Proteína de fusión

ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPSKSPFF NTSVVYKTL 50
 FVEFTDHLFN IAKPRFPWMG LLGPTIQAEV YDTVTITLKN MASHFVSLHA 100
 VGVSYWKASE GAEDYDDTSQ REEDDRVFP GGSHTYVWQV LKENGPMASD 150
 FLCLTYSYLS HYDVLVDLNS GLIGALLVCR EGSLLAKEKQ TLHKKFLIFLA 200
 VFDEKSWHS ETKNSLMQDR DAASARAWFK MHTVNGVYNR SLPLIGCHH 250
 KSVYVHVIGM GTTFEVSIF LECHTFLVRN HRQASLEISF ITFLTAQTLL 300
 MDLQGLLFC HISSHQHDM EAYVKVDSCP EEPQLRMKN EEAEDYDDL 350
 TDSEMDVVRF DDDNSPSFIQ IRSVAKHFK TWVHYIAEE EDWDYAPLVL 400
 APDRSYKSO YLNNQPRIG RYKVKRFMA YTDFTFKTRE AIQHESGILG 450
 PLLYGEVGD TLLIFKNQAS RYNYIYPHGI TDVRPLYSRRLPKGVKHLKD 500
 FFLPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSFVNME RDLASGLIG 550
 LLIICYKESVD QRGNQMSDK RNVLFSVFD ENRSWYLTEN IQRFLNFPAG 600
 VQLEDPEFQA SNIMHSINGY VFDLSQLSVC LHEVAYWYIL SIGAQTFDLS 650
 VVFSGYTFKH KMYVEDTLTL PFFSGETVFM SMENPGLWIL GCHNSDFNR 700
 GMTALLKVS CDKNTGYYE DSYEDISAYL LSKNNAIEPR SFSQNPVLK 750
 RHQREITRTT LQSDQEEIDY DDTISVEMKK EDFDIYDEDE NQSPRSFQKK 800
 TRHYFIAAVE RLWDYGMSS PHVLNRQAQS GSVFQFKVV FQFTDGSFT 850
 QFLYRGELNE HGLLGPYIR AEVEDNIMVT FRNQASRPYS FYSSLSIYEE 900
 DQRQGAEPK RFVKPHETKT YFWKQHHMA FTKDEFCKA WAYFSVDLE 950
 KDVHSGILIP LVCHEWTLN PARGRQVTVQ EFALFFTIQ ETKSWFFEN 1000
 MERNCRAPCN IQMEDPTFKK NYTFHAINCY IMDTLGLVM AQDQIRWYL 1050
 LSMGSENIH SIHPSGHVPT VRKEEYKMA LYNLPGVFE TVEMLSKAC 1100
 IWRVECLIGE HLHAGMTLF LVYNSKQCTP LGMASGHIRD FQITASGQYG 1150
 QWAPKLARLH YSGINAWST KEFWSIKVD LLAPMIHIG KTQGARQKFS 1200
 SLYISQFIM YSLDGKWKQT YRGNSTGTLM VFFGNVDSSG IKHNIFNPT 1250
 IARYIRLHPT HYSIRSTLRN ELMGCDLNSC SEMPLMESKA ISDAQITASS 1300
 YFTNMFAWTS PSKARHLQG RSNMWRQVFN NPKEWLQVDF QKTMKVTGV 1350
 TQGVKSLTS MYVKEFLISS SQDGHQWTLF FQNGKVKVF GNQDSFTPV 1400
 NSLDGPFLLTR YLRIHPQSWV HQIALRMEVL GCEAQDLYDK THTCPCFPAP 1450
 ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV 1500
 EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAP 1550
 EKTISKAKGQ PREPQVYTLF PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE 1600
 SNGQPENNYK TTPPVLDSDG SFPLYSKLTV DKSRWQGGV FSCSVMEAL 1650
 HNHYTQKSL LSPG 1664


Immunoglobulin Fc fragment / fragment Fc d'immunoglobuline / fragmento Fc de

immunoglobulina

DKHTCPPCP APELLGGPSV FLPPPKFDDT LMSRTPEVT CVYVDVSHED 50'
 PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVSVLTVLH QDLWNGKEYK 100'
 CKVSNKALPA PIEKTSKAK GQPREPQVYT LPSPRDELTK NQVSLTCLVK 150'
 GFYPSDIAVE WESNGQPKNN YKTTTPVLDG DGSFPLYSKL TVDKSRWQGG 200'
 NVFSCSVME ALHNHYTQKS LSLSPG 226'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 6'-1444 9'-1447 41'-101' 147'-205' 153-179 248-329 528-554
 630-711 938-964 1005-1009 1127-1275 1280-1432 1479-1539 1585-1643

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-41 Asn-77 Asn-239 Asn-916 Asn-1224 Asn-1515

efpeglenatidum #

efpeglenatide

exenatide derivative and human IgG4 Fc dimer linked together with polyethylene glycol derivative:
 $N^{6,27}, N^{1,9}$ -[ω -(oxypropane-1,3-diyl)- α -(propane-1,3-diyl)poly(oxyethylene)] [1-(imidazol-4-ylacetic acid)]exendin-4 *Heloderma suspectum* (Gila monster), human immunoglobulin G4 Fc fragment-(9'-229')-peptide dimer (11'-11'')-disulfide

efpèglénatide

dérivé de l'exénatide et du dimère de l'IgG4 Fc liés par un pont dérivé du polyéthylèneglycol :
 $N^{6,27}, N^{1,9}$ -[ω -(oxypropane-1,3-diyl)- α -(propane-1,3-diyl)poly(oxyéthylène)] [1-acide (imidazol-4-yl)acétique]exendine-4 *Heloderma suspectum* (monstre de Gila), fragment Fc de l'immunoglobuline G4 humaine-(9'-229')-peptide (11'-11'')-disulfure du dimère

efpeglenatida

derivado de la exenatida y del dímero de la IgG4 Fc unidos por un puente derivado del polietilenglicol :
 $N^{6,27}, N^{1,9}$ -[ω -(oxipropano-1,3-diil)- α -(propano-1,3-diil)poli(oxitileno)] [1-ácido (imidazol-4-il)acético]exendina-4 *Heloderma suspectum* (monstruo de Gila), fragmento Fc de la inmunoglobulina G4 humana-(9'-229')-péptido (11'-11'')-disulfuro del dímero

Modified exendin-4 / Exendine-4 modifiée / Exendina-4 modificada


HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS 39

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4
 PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50 '
 EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100 '
 YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150 '
 VKGFYPSDIA VEWESNGQPE NNYKTTTPVL DSDGSFFLYS RLTVDKSRWQ 200 '
 EGNVFCSCVM HEALHNHYTQ KSLSLSLGK 229 '

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero del Fc de hIGHG4
 PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50 '
 EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100 '
 YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150 '
 VKGFYPSDIA VEWESNGQPE NNYKTTTPVL DSDGSFFLYS RLTVDKSRWQ 200 '
 EGNVFCSCVM HEALHNHYTQ KSLSLSLGK 229 '

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 11'-11'' 43'-103' 43'-103'' 149'-207' 149'-207''

Modified residues / Résidus modifiés / Restos modificados

**emactuzumabum #**

emactuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody;
 gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimer (225-225'':228-228'')-bisdisulfide

émactuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens*IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (225-225":228-228")-bisdisulfure

emactuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 estimulante de colonias, CSF-1R, CSF-1-R, receptor del factor 1 estimulante de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV1-18*01 (92.90%) -(IGHD)-IGHJ6*01) [8.7.10] (1-116) -*Homo sapiens* IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYDISWVRQA	PGQGLEWMGV	50
IWTDGGTNYA	QKLQGRVTMT	TDSTSTAYM	ELRSLRSDDT	AVYYCARDQR	100
LYFDVWGQGT	TVTYSSASTK	GPSVFPLAPS	SKSTSGGTAA	LGCLVKDYFP	150
EPVTVSWNSG	ALTSVGHVTFP	AVLQSSGLYS	LSSVVTVPSS	SLGTQTYICN	200
VNHKPSNTKV	DKKVEPKSCD	KTHTCPPCPA	PELLGGPSVF	LFPKPKDTL	250
MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	REEQYNSTYR	300
VVSVLTVLHQ	DWLNGKEYKC	KVSNKALPAP	IEKTIKAKG	QPREPQVYTL	350
PPSRDELTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTPPVLDS	400
GSFFLYSKLT	VDKSRWQQGN	VFSCSVMEHA	LHNHYTQKSL	SLSPGK	446

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGRVIT	ITCRASEDVN	TVSWYQQKP	GKAPKLLIYA	50
ASNRYTGVP	RFGSGSGSDT	FTLTISLQAP	EDFATYYCQ	SFSYPTFGQG	100
TKLEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNFFYP	REAKVQWKVD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLT	L SKADYERHKV	YACEVTHQGL	200
SSPVTKSFNR	GEC				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	143-199	260-320	366-424
	22"-95"	143"-199"	260"-320"	366"-424"

Intra-L (C23-C104)	23'-88'	133'-193'
	23"-88"	133"-193"

Inter-H-L (h 5-CL 126)	219-213'	219"-213"
------------------------	----------	-----------

Inter-H-H (h 11, h 14)	225-225"	228-228"
------------------------	----------	----------

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
296, 296"

emibetuzumabum

emibetuzumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor receptor, HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-Met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody;
gamma4 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)), IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (221-221":224-224")-bisdisulfide

émibétuzumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)), IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-215')-disulfure avec la chaîne légère kappa (1'-215')] [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01 [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215'))]; dimère (221-221":224-224")-bisdisulfure

emibetuzumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MET (proto-oncogén met, receptor del factor de crecimiento de hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-441) [VH humanizada (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ5*01 L123>T (110) (1-115)), IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K2>del (441)) (116-441)], (129-215')-disulfuro con la cadena ligera kappa (1'-215')] [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (84.40%) -IGKJ4*01 [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215'))]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SKKASGYTFT DYYMHWVRQA PGQGLEWMGR 50
VNPNRRTGTTY NQKFEGRVTM TTDSTSTAY MELRSLRSDD TAVYCARAN 100
WLDYWGQGT VTSVSSATKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVTPSSS LGTKTYTCNV 200
DHKPSNTRKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLNL GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNN YTKQSLSLSL G 441

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPFS LSAVSGDRVT ITCSVSSSVS SIYLHWYQOK PGKAPKLLIY 50
STSNLASGVP SRFSQSGST DFTLTISLQ PEDFATYYCO VYSGYPLTFG 100
GSTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEK 215

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 142-198 256-316 362-420
22"-96" 142"-198" 256"-316" 362"-420"

Intra-L (C23-C104) 23'-89' 135'-195'
23'''-89''' 135'''-195'''

Inter-H-L (CH1 10-CL 126) 129-215' 129"-215"
Inter-H-H (h 8, h 11) 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
292, 292"

Other post-translational modifications

Autres modifications post-traductionnelles

Otras modificaciones post-traduccionales

Lacking H chain C-terminal lysine (CHS K2>del)

enadenotucirevum #

enadenotucirev

chimeric oncolytic adenovirus Ad3/Ad11p containing two deletions in the viral genome in the E3 region (2444 bp) and in the E4 region (24 bp) and 197 non-homologous nucleotides in the E2B region

énadénotucirev

adénovirus chimérique oncolytique Ad3/Ad11p contenant deux suppressions dans le génome viral, dans la région E3 (2444 pb) et dans la région E4 (24 pb) et 197 nucléotides non-homologues dans la région E2B

enadenotucirev

adenovirus quimérico oncolítico Ad3/Ad11p que contiene dos deleciones en el genoma viral, en la región E3 (2444 pb) y en la región E4 (24 pb) y 197 nucleótidos no-homólogos en la región E2B

enceniclinum

encenicline


N-[(3*R*)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide

encénicline

N-[(3*R*)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophène-2-carboxamide

enceniclina

N-[(3*R*)-1-azabicyclo[2.2.2]octan-3-il]-7-cloro-1-benzotiofeno-2-carboxamida

 $C_{16}H_{17}ClN_2OS$
**esuberaprostum**

esuberaprost


(+)-4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hydroxy-1-[(1*E*,3*S*,4*S*)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3*a*,8*b*-tetrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl]butanoic acid

ésubéraprost

(+)-acide4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hydroxy-1-[(1*E*,3*S*,4*S*)-3-hydroxy-4-méthyloct-1-én-6-yn-1-yl]-2,3,3*a*,8*b*-tétrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl]butanoïque

esuberaprost

(+)-ácido 4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hidroxi-1-[(1*E*,3*S*,4*S*)-3-hidroxi-4-metiloct-1-en-6-in-1-il]-2,3,3*a*,8*b*-tetrahidro-1*H*-ciclopenta[*b*][1]benzofuran-5-il]butanoico



evofosfamidum
evofosfamide



(1-methyl-2-nitro-1*H*-imidazol-5-yl)methyl *N,N'*-bis(2-bromoethyl)phosphorodiamidate

évofosfamide

N,N'-bis(2-bromoéthyl)phosphorodiamidate de (1-méthyl-2-nitro-1*H*-imidazol-5-yl)méthyle

evofosfamida

N,N'-bis(2-bromoetil)fosforodiamidato de (1-metil-2-nitro-1*H*-imidazol-5-il)metilo



ferricum maltolum
ferric maltol



tris(2-methyl-4-oxo-κ*O*-4*H*-pyran-3-olato-κ*O*)iron(III)

maltol ferrique

tris(2-méthyl-4-oxo-κ*O*-4*H*-pyran-3-olato-κ*O*)fer(III)


maltol férrico

tris(2-metil-4-oxo-κ*O*-4*H*-piran-3-olato-κ*O*)hierro(III)



filociclovirum
filociclovir

2-amino-9-[(*Z*)-[2,2-bis(hydroxymethyl)cyclopropylidene]methyl]-1,9-dihydro-6*H*-purin-6-one

filociclovir	2-amino-9-((Z)-[2,2-bis(hydroxyméthyl)cyclopropylidène]méthyl)-1,9-dihydro-6H-purin-6-one
filociclovir	2-amino-9-((Z)-[2,2-bis(hydroximetil)ciclopropilideno]metil)-1,9-dihidro-6H-purin-6-ona
	$C_{11}H_{13}N_5O_3$
	
firivumabum # firivumab	immunoglobulin G1-kappa, anti-[influenza A virus hemagglutinin HA], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-453) [<i>Homo sapiens</i> VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (232-232":235-235")-bisdisulfide
firivumab	immunoglobuline G1-kappa, anti-[hémagglutinine HA du virus de la grippe A], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232":235-235")-bisdisulfure
firivumab	immunoglobulina G1-kappa, anti-[hemagglutinina HA del virus de la gripe A], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV1-69*01 (86.70%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*03 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 E12>D (362), M14>L (364), A110>G (437) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-15*01 (83.20%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKMPGSSVKV SCKTSGVFFS SHAISWVRQA PGQGLEWMGG 50
 ISPMFGTTHY AQKFQGRVTI TADQSTTTAY MELTSLTSED TAVYYCARDG 100
 AGSYYPNLWF DPWGQGTIVT VSSASTKGPS VFPLAPSSKS TSGGTAAALGC 150
 LVKDYFFPEFV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
 TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSTVFLFP 250
 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNNWVDGVEV HNAKTKFREE 300
 QINSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
 EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQFPENNYKTS 400
 FVLDSDDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEGLHN HYTKQKSLSLG 450
 PGK 453

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPAT LSLSPGERAT LSCRASENIW NNLAWYQQKP GQAPRLISG 50
 ASTGATGVPS RFRGSGSRTE FTLTISLQS EDFAIYFCQQ YNSWPRTFGP 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYSLSSILT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 150"-206" 267"-327" 373"-431"
 22"-96" 150"-206" 267"-327" 373"-431"

Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"

Inter-H-L (h 5-CL 126) 226"-214" 226"-214"

Inter-H-H (h 11, h 14) 232"-232" 235"-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 303, 303"

fosdagrocoratum

fosdagrocorat

(2*R*,4*a*S,10*aR*)-4*a*-benzyl-7-[(2-methylpyridin-3-yl)carbamoyl]-2-(trifluoromethyl)-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthren-2-yl dihydrogen phosphate


fosdagrocorat

dihydrogénophosphate de (2*R*,4*a*S,10*aR*)-4*a*-benzyl-7-[(2-méthylpyridin-3-yl)carbamoyl]-2-(trifluorométhyl)-1,2,3,4,4*a*,9,10,10*a*-octahydrophénanthrén-2-yle

fosdagrocorat

dihidrógenofosfato de (2*R*,4*a*S,10*aR*)-4*a*-bencil-7-[(2-metilpiridin-3-il)carbamoi]-2-(trifluorometil)-1,2,3,4,4*a*,9,10,10*a*-octahidrofenantren-2-ilo

C₂₉H₃₀F₃N₂O₅P



funapidum

funapide



(3'*S*)-1'-[[5-(trifluoromethyl)furan-2-yl]methyl]-2*H*,6*H*-spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'-(1'*H*)-one

funapide

(3'*S*)-1'-[[5-(trifluorométhyl)furan-2-yl]méthyl]-2*H*,6*H*-spiro[furo[2,3-*f*][1,3]benzodioxole-7,3'-indol]-2'-(1'*H*)-one

funapida

(3'*S*)-1'-[[5-(trifluorometil)furan-2-il]metil]-2*H*,6*H*-espiro[furo[2,3-*f*][1,3]benzodioxol-7,3'-indol]-2'-(1'*H*)-ona



furaprevirum
furaprevir


cyclopentyl {(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-14*a*-[(1-methylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-[(propan-2-yl)oxy]phenyl}benzofuro[3,2-*d*]pyrimidin-4-yl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecin-6-yl}carbamate

furaprévir

{{(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-14*a*-[(1-méthylcyclopropane-1-sulfonamido)carbonyl]-2-[(2-{4-[(propan-2-yl)oxy]phényl}benzofuro[3,2-*d*]pyrimidin-4-yl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécin-6-yl}carbamate de cyclopentyle

furaprevir

{{(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-14*a*-[(1-metilciclopropano-1-sulfonamido)carbonil]-2-[(2-{4-[(propan-2-il)oxi]fenil}benzofuro[3,2-*d*]pirimidin-4-il)oxi]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13*a*,14,14*a*,15,16,16*a*-hexadecahidrociopropana[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecin-6-il}carbamato de ciclopentilo



gedatolisibum
gedatolisib


N-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-*N'*-(4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl)urea

gédatolisib

N-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-*N'*-(4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phényl)urée

gedatolisib

N-(4-[[4-(dimetilamino)piperidin-1-il]carbonil]fenil)-
N'-{4-[4,6-di(morfolin-4-il)-1,3,5-triazin-2-il]fenil}urea

C₃₂H₄₁N₉O₄

glasdegibum
 glasdegib


N-[(2*R*,4*R*)-2-(1*H*-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-*N'*-(4-cyanophenyl)urea

glasdégib

N-[(2*R*,4*R*)-2-(1*H*-benzimidazol-2-yl)-1-méthylpipéridin-4-yl]-*N'*-(4-cyanophényl)urée

glasdegib

N-[(2*R*,4*R*)-2-(1*H*-benzoimidazol-2-il)-1-metilpiperidin-4-il]-*N'*-(4-cianofenil)urea

C₂₁H₂₂N₆O

idasanutlinum
 idasanutlin



4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxamido]-3-methoxybenzoic acid

idasanutline

acide 4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-chloro-2-fluorophényl)-4-(4-chloro-2-fluorophényl)-4-cyano-5-(2,2-diméthylpropyl)pyrrolidine-2-carboxamido]-3-méthoxybenzoïque

idasanutlina

ácido 4-[(2*R*,3*S*,4*R*,5*S*)-3-(3-cloro-2-fluorofenil)-4-(4-cloro-2-fluorofenil)-4-ciano-5-(2,2-dimetilpropil)pirrolidina-2-carboxamido]-3-metoxibenzoico



imalumabum #
imalumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MIF (macrophage migration inhibitory factor, glycosylation-inhibiting factor, GLIF, GIF)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide

imalumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MIF (facteur inhibiteur de la migration des macrophages, facteur inhibant la glycosylation, GLIF, GIF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure

imalumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* MIF (factor inhibidor de la migración de macrófagos, factor inhibidor de la glicosilación, GLIF, GIF)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (92.80%) -(IGHD)-IGHJ3*01) [8.8.11] (1-118) -IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS 50
 IGSSGGTTY ADSVKGRFTI SRDnskNTLY LQMNslRAED TAVYYCAGSQ 100
 WLYGMDVWQG GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FFEPTVTSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200
 CNVNHKPSNT KVDKRVPEKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGEVHNAKT KPREEQYNST 300
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 TLPSPREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQFEN NYKTTTPPVL 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRDVT ITCRSSQRM TYLNWYQQKPK GKAPKLLIFV 50
 ASHSQSGVPS RFRGSGSETD FTLTISGLQP EDSATYYCQQ SFWTFLTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22'-96' 145"-201' 262-322 368-426
 22"-96" 145"-201" 262"-322" 368"-426"

Intra-L (C23-C104) 23'-88' 134'-194'
 23"-88" 134"-194"

Inter-H-L (h 5-CL 126) 221-214' 221"-214"

Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 298, 298"

indoximodum

indoximod


1-methyl-D-tryptophan

indoximod

1-méthyl-D-tryptophane

indoximod

1-metil-D-triptófano

C₁₂H₁₄N₂O₂**lemborexantum**

lemborexant


(1*R*,2*S*)-2-[[[(2,4-dimethylpyrimidin-5-yl)oxy]methyl]-
 2-(3-fluorophenyl)-*N*-(5-fluoropyridin-
 2-yl)cyclopropanecarboxamide

lemborexant

(1*R*,2*S*)-2-[[[(2,4-diméthylpyrimidin-5-yl)oxy]méthyl]-
 2-(3-fluorophényl)-*N*-(5-fluoropyridin-
 2-yl)cyclopropanecarboxamide

lemborexant

(1*R*,2*S*)-2-[[[(2,4-dimetilpirimidin-5-il)oxi]metil]-
 2-(3-fluorofenil)-*N*-(5-fluoropiridin-
 2-il)ciclopropanocarboxamida

C₂₂H₂₀F₂N₄O₂

lenzilumabum #

lenzilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

lenzilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

lenzilumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* CSF2 (factor 2 estimulante de colonias (granulocitos-macrófagos), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV1-3*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (85.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SCKASGYST NYIHWVRQA PGQRLEWMGW 50
INAGNGNTKY SQKFQGRVTI TRDTSASTAY MELSSLRSED TAVYYCVRRQ 100
RFPYYFDYNG QGTLTVTVSSA STKGPSVFFL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TTPAVLQSSG LSLSSSVTV FSSSLGTQTY 200
ICNVNHPKFN TRVDKVEPK SCDKTHTCPP CPAPELLGGP SVFLPPEPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSKNAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTFPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFCSVM HEALNHYTQ KSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

EIVLTQSPAT LSVSPGERAT LSCRASQSVG TNVAVYQQK GPAPRVLIYS 50
TSSRATGTD RFSGSGSGTD FTLTISRLEP EDFAVYCCQ FNKSPITFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFF PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22°-96" 146°-202" 263°-323" 369°-427"
 22°-96" 146°-202" 263°-323" 369°-427"

Intra-L (C23-C104) 23°-88" 134°-194"
 23°-88" 134°-194"

Inter-H-L (h 5-CL 126) 222°-214" 222°-214"

Inter-H-H (h 11, h 14) 228°-228" 231°-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 299, 299"

lonoctocogum alfa #

lonoctocog alfa

recombinant DNA derived B domain deleted single-chain human blood coagulation factor VIII, produced in Chinese hamster ovary (CHO) D944 cells, glycoform alfa: des-(765-1652)-human blood coagulation factor VIII (antihemophilic factor, procoagulant component)

lonoctocog alfa

facteur VIII de coagulation humain dont le domaine B a été supprimé, chaîne unique, produit par les cellules ovariennes de hamsters chinois (CHO) D944 à partir d'ADN recombinant, forme glycosylée alfa; dès-(765-1652)-facteur VIII de coagulation humain (facteur antihémophilique, composé procoagulant)

lonoctocog alfa

factor VIII de coagulación humano al que se ha suprimido el dominio B, monocatenario, producido por células ováricas de hamster chino (CHO) D944 a partir de ADN recombinante, forma glicosilada alfa; des-(765-1652)-factor VIII de coagulación humano (factor antihemofílico, componente procoagulante)

Sequence / Séquence / Secuencia

```


ATTRYYLGAV  ELSWDYMQSD  LGELPVDARF  PPRVPKSFPF  NTSVYVKKTL  50
FVEFTDHLFN  IAKFRPPWMG  LLGPTIQAEV  YDTVVITLKN  MASHPVSLLHA  100
VGVSYWKASE  GAEYDDQTSQ  REKEDDKVPF  GGSHTYVWQV  LKENGPMASD  150
PLCLTSYSL  HVDLVKDLNS  GLIGALLVCR  EGSLAKEKTO  TLHKFILLFA  200
VFDEGKSWHS  ETKNSLMQDR  DAASARAWPK  MHTVNGYVNR  SLPLIGLCHR  250
KSVYVHVGIM  GTTPEVHSIF  LEGHTFLVRN  HRQASLEISP  ITFLTAQTLL  300
MDLGQFLLFC  HISSHQHDGM  EAYVKVDSCP  EEPQLRMKN  EEAEDYDDDL  350
TDSEMDVVRP  DDDNSPFSFIQ  IRSVAKKHFK  TWVHYIAAEE  EDWDYAPLVL  400
APDDRSYKSK  YLNNGPQRIG  RKYKKVREMA  YTDETFKTR  AIQHESSGILG  450
PILLYGVGDT  LLIIFKQAS  RPYNIYPHGI  TDVRLPLYSR  LPKGVKHLKD  500
FPIIPGEIFK  YKVVTVVDEG  PTKSDPRCLT  RYVSSFNME  RDLASGLIG  550
LLICYKESVD  QRGNQIMSDK  RNVLFSVFD  ENRSWLTEN  IQRFLPNAG  600
VQLEDPEFQA  SNIMHSINGY  VFDSLQLSVC  LHEVAYWVIL  SIGAQTFELS  650
VFFSGYTFKH  KMYVEDTLTL  PFSGETVFM  SMENPGLWIL  GCHNSDFRNR  700
GMTALLKVSS  CDKNTGDYXE  DSYEDISAYL  LSKNNAIEPR  SFSQNSRHP  750
TRQKQFNATT  IPENTTLQSD  QEBIDYDDTI  SVEMKKEDFD  IYDEDENQSP  800
RSFQKKTRHY  FIAAVERLWD  YGMSSSHVL  RNRAQSGSVP  QFKKVVFQEP  850
TDGSFTQPLY  RGELEHGL  LGPYIRAEVE  DNIMVTFRNQ  ASRPYSFYSS  900
LISYEEDQRQ  GAEPKKNFVK  PNETKTYFWK  VQHHMPTKD  EFDCKAWAYF  950
SDVDLEKDVH  SGLIGPLLVC  HTNTLNPAHG  RQVTVQEFAL  FFTIFDETKS  1000
WYFTENMERN  CRAPCNQME  DPTFKENYRF  HAINGYIMDT  LPGLVMAQDQ  1050
RIRWYLLSMG  SNENIHSIH  FSGHVFTVRK  EYKMALYNL  YPGVFETVEM  1100
LPSKAGIWRV  ECLIGELH  AGMSTLFLVY  NKCQTPGLMA  SGHIRDFQIT  1150
ASGQYQWAP  KLARLHYS  GSNINAWSTKE  PFWIKVDLLA  PMIHGIKTQ  1200
ARQKFSSLYI  SQFIIMYSL  DGGKWKTYRGN  STGTLMVFEG  NVDSGSIKHN  1250
IFNPPIIARY  IRLHPTHYSI  RSTLRMLMG  CDLNSCSMPL  GMESKAISDA  1300
QITASSYFTN  MFATWSPSKA  RLHLQGRSNA  WRQVNNFKE  WLQVDFQKTM  1350
KVTGVTTQGV  KSLLTSMYK  EFLISSSQDG  HQWTLFFQNG  KVKVFQGNQD  1400
SFTFVVNSLD  FPLLTRYLRI  HPQSWVHGIA  LRMEVLGCEA  QDLY  1444

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 944-970 1011-1015 1133-1281 1286-1438

Modified residues / Résidus modifiés / Restos modificados

Y
346-718-719-723-776-792
O-sulfo Tyr



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-41 Asn-239 Asn-757 Asn-764 Asn-922 Asn-1230

Glycosylation site (Q) / Site de glycosylation (Q) / Posición de glicosilación (Q)

Ser-743

lulizumabum pegolum #

lulizumab pegol

immunoglobulin V-kappa pegylated, anti-[*Homo sapiens* CD28 (TP44, T cell specific surface glycoprotein CD28)], humanized monoclonal antibody; V-kappa domain (1-107) [humanized V-KAPPA (*Homo sapiens* IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugated via a linker of the maleimide group (thioether bond with cysteinyl 86 (70)) to two linear chains of methoxy polyethylene glycol 20 (mPEG20)

lulizumab pégol	immunoglobuline V-kappa pégylé, anti-[<i>Homo sapiens</i> CD28 (TP44, glycoprotéine de surface CD28 spécifique des cellules T)], anticorps monoclonal humanisé; domaine V-kappa (1-107) [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginyl (108); conjugué via un linker du groupe maléimide (liaison thioéther avec cystéinyl 86 (70)) à deux chaînes linéaires de méthoxy polyéthylène glycol 20 (mPEG20)
lulizumab pegol	immunoglobulina V-kappa pegilada, anti-[<i>Homo sapiens</i> CD28 (TP44, glicoproteína de superficie CD28 específico de células T)], anticuerpo monoclonal humanizado; dominio V-kappa (1-107) [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV1D-13*01 (84.30%) D86>C (70) -IGKJ1*01 G119>S (99)) [6.3.9] (1-107)] -arginil (108); conjugado mediante conector del grupo maleimida (unión tioéter con cisteinil 86 (70)) con dos cadenas lineales de metoxi polietilén glicol 20 (mPEG20)
	DIQMTQSPSS LSASVGDRVT ITCRASPIW PFLEWYQQKPK GKAPKLLIYF 50 TSRLRHGVPS RFGSGSGSTC FTLTISSLQP EDFATYYCLQ NVANPATFSQ 100 GTKVEIKR 108 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-L (C23-C104) 23-88 Pegylation site / Site de pegylation / Posición de pegilación D86>C: 70
lumretuzumabum # lumretuzumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], humanized monoclonal antibody; gamma1 heavy chain (1-449) [humanized VH (<i>Homo sapiens</i> IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01(CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)],(223-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; dimer (229-229":232-232")-bisdisulfide
lumrétuzumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-449) [VH humanisé (<i>Homo sapiens</i> IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01(CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)],(223-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') - <i>Homo sapiens</i> IGKC*01 (114'-220')]; dimère (229-229":232-232")-bisdisulfure

lumretuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (93.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFR SSIYSWVRQA PGQGLEWMGW 50
 IYAGTGSPSY NQKLQGRVTM TTDSTSTAY MELRSLRSD TAVYYCARHR 100
 DYYNSLTYW GQGLTIVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSVVT VPSSSLGTQT 200
 YICNVNPKFS NTKVDKKVEP KSCDKTHCTPC PCPAPPELLGG PSVFLFPPKP 250
 KDTLMISRTPEVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
 VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
 LDSGGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSQSVL NSGNQKNYLT WYQQKPGQPP 50
 KLLIYWASTR ESGVPDRFSG SGSSTDFTLT ISSLQAEDVA VYQCSDYSY 100
 PYTFQGQTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 23-94" 140"-200"
 23"-94"" 140""-200""

Inter-H-L (h 5-CL 126) 223-220" 223"-220"

Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

Enriched in bisected non-fucosylated oligosaccharides

Enrichi en oligosaccharides non-fucosylés bisectés

Enriquecido con oligosacáridos bisecados no fucosilados

Other post-translational modifications

Autres modifications post-traductionnelles

Otras modificaciones post-traduccionales

Lacking H chain C-terminal lysine (CHS K2>del)

merotocinum

merotocin

N-(4-sulfanylbutoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyll-asparaginyll-L-cysteinyl-*N*-[(4-fluorophenyl)methyl]glycyl-L-leucylglycinamide cyclic (1-5)-thioether


mérotocine

(1-5)-thioéthercyclique du *N*-(4-sulfanylbutoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyll-asparaginyll-L-cystéinyl-*N*-[(4-fluorophényl)méthyl]glycyl-L-leucylglycinamide

merotocina

(1-5)-tioetercíclico del *N*-(4-sulfanilbutanoil)-L-tirosil-L-isoleucil-L-glutaminil-L-asparaginil-L-cisteinil-*N*-[(4-fluorofenil)metil]glicil-L-leucilglicinamida

C₄₈H₆₈FN₁₁O₁₂S



mibenratidum

mibenratide

an 18 amino acid cyclic peptide largely homologous to amino acids 202-220 of the β_1 -adrenergic receptor second extracellular loop (AR-ECII) that binds to anti- β_1 -AR pathological autoantibodies:



cyclo(L-alanyl-L-arginyl-L-arginyl-L-cysteinyl-L-tyrosyl-L-asparaginyl-L- α -aspartyl-L-prolyl-L-lysyl-L-cysteinyl-L-seryl-L- α -aspartyl-L-phenylalanyl-L-valyl-L-glutamyl-L-alanyl-L- α -aspartyl-L- α -glutamyl), cyclic (4-10)-disulfide

mibenratide

peptide cyclique de 18 acides aminés largement homologue aux acides aminés 202-220 de la seconde boucle extracellulaire de l'adrénorécepteur β_1 (AR-ECII) qui se lie aux autoanticorps anti- β_1 -AR pathologiques: (4-10)-disulfure cyclique du cyclo(L-alanyl-L-arginyl-L-arginyl-L-cystéinyl-L-tyrosyl-L-asparaginyl-L- α -aspartyl-L-prolyl-L-lysyl-L-cystéinyl-L-séryl-L- α -aspartyl-L-phénylalanil-L-valyl-L-glutamyl-L-alanyl-L- α -aspartyl-L- α -glutamyl)

mibenratida

péptido cíclico de 18 aminoácidos altamente homólogo a los aminoácidos 202-220 del segundo bucle extracelular del adrenoreceptor β_1 (AR-ECII) que se une a los autoanticuerpos anti- β_1 -AR patológicos: (4-10)-disulfuro cíclico del ciclo (L-alanil-L-arginil-L-arginil-L-cisteinil-L-tirosil-L-asparaginil-L- α -aspartil-L-prolil-L-lisil-L-cisteinil-L-seril-L- α -aspartil-L-fenilalanil-L-valil-L-glutaminil-L-alanil-L- α -aspartil-L- α -glutamil)

**modimelanotidum**

modimelanotide



acetylhexa-L-lysyl[human melanotropin alpha (alpha-MSH)]

modimélanotide

acétylhéxa-L-lysyl[mélanotropine alpha humaine (alpha-MSH)]

modimelanotida

acetilhéxa-L-lisil[melanotropina alfa humana (alfa-MSH)]



mongersenenum

mongersen


all-P-ambo-2'-deoxy-P-thioguananylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguananylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguananylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguananylyl-(3'→5')-2'-deoxycytidine

mongersen

tout-P-ambo-2'-déoxy-P-thioguananylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguananylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguananylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thioguananylyl-(3'→5')-2'-déoxycytidine

mongersén

todo-P-ambo-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxicitidina

C₂₀₀H₂₆₁N₆₉O₁₀₇P₂₀S₂₀(3'-5')d(P-thio)(G-T-m⁵C-G-C-C-C-C-T-T-C-T-C-C-m⁵C-G-C-A-G-C)**napabucasinum**

napabucasin


2-acetylnaphtho[2,3-*b*]furan-4,9-dione

napabucasine

2-acétylnaphtho[2,3-*b*]furan-4,9-dione

napabucasina

2-acetilnafto[2,3-*b*]furan-4,9-diona



odasvirum
odasvir



dimethyl *N,N'*-(1,4(1,4)-dibenzenacyclohexaphane-1²,4²-diylbis{1*H*-benzimidazole-5,2-diyl}[(2*S*,3*aS*,7*aS*)-octahydro-1*H*-indole-2,1-diyl][(2*S*)-3-methyl-1-oxobutan-1,2-diyl])biscarbamate

odasvir

N,N'-(1,4(1,4)-dibenzénacyclohexaphane-1²,4²-diylbis{1*H*-benzimidazole-5,2-diyl}[(2*S*,3*aS*,7*aS*)-octahydro-1*H*-indole-2,1-diyl][(2*S*)-3-méthyl-1-oxobutan-1,2-diyl])biscarbamate de diméthyle

odasvir

N,N'-(1,4(1,4)-dibencenaclohexafano-1²,4²-diilbis{1*H*-benzoimidazol-5,2-diil}[(2*S*,3*aS*,7*aS*)-octahidro-1*H*-indol-2,1-diil][(2*S*)-3-metil-1-oxobutan-1,2-diil])biscarbamato de dimetilò



olipudasum alfa #
olipudase alfa

recombinant DNA derived des-(1-13)-human sphingomyelin phosphodiesterase (acid sphingomyelinase, EC-3.1.4.12), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

olipudase alfa

dès-(1-13)-sphingomyéline phosphodiesterase humaine (sphingomyélinase acide, EC-3.1.4.12), produite par des cellules ovariennes de hamster chinois à partir d'ADN recombinant, forme glycosylée alfa

olipudasa alfa

des-(1-13)-esfingomielina fosfodiesterasa humana (esfingomielinasa ácida, EC-3.1.4.12), producida en células ováricas de hamster chino a partir de ADN recombinante, forma glicosilada alfa

Sequence / Séquence / Secuencia

```

HPLSPQG HPARLHRIVP RLRDVFQWGN LTCPICKGLF 50
TAINLGLKKE PNVARVGSVA IKLCNLLKIA PPAVCQSIVH LFEDDMVEVM 100
RRSVLSPSEA CGLLLGSTCG HWDIFSSWNI SLPTVPKPPP KPPSPAPGA 150
PVSRIFLFTD LHWHDYLEG TDPDCADFLC CRRGSLPPA SRPGAGYWGE 200
YSKCDLFLRT LESLSSGLGF AGPDMVYWT GDIPAHDVWH QTRQDQLRAL 250
TTVTALVRKF LGPVFVYPAV GNHSTPVNS FPPPFIEGNH SSRWLYEAMA 300
KAWEPWLP AE ALRTLRI GGF YALSPYPGLR LISLNMNFC S RENFWLLINS 350
TDPAGQLQWL VGE LQAADR GDKVHIIGHI PPGHCLKSWS WNYRIVARY 400
ENTLAAQFFG HTHVDFEFV YDEETLSRPL AVAFAPSAT TYIGLNPGYR 450
VYQIDGNYSG SSHVLDHET YILNLTQANI PGAIPHQQL YRARETYGLP 500
NTLPTAHHNL VYMRGDMQL FQTFWFLYHK GHPPSEPCGT PCRLATLCAQ 550
LSARADSPAL CRHLPDGLS PEAQSLWFRP LFC 583

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 43-119 46-111 74-85 175-180 181-204 339-385 538-542 548-561

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-40 Asn-129 Asn-289 Asn-349 Asn-457 Asn-474

omipalisibum
 omipalisib

2,4-difluoro-*N*-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide


omipalisib

2,4-difluoro-*N*-{2-méthoxy-5-[4-(pyridazin-4-yl)quinoléin-6-yl]pyridin-3-yl}benzènesulfonamide

omipalisib

2,4-difluoro-*N*-{2-metoxi-5-[4-(piridazin-4-il)quinolein-6-il]piridin-3-il}bencenosulfonamida

C₂₅H₁₇F₂N₅O₃S



orilotimodum
 orilotimod

D-γ-glutamyl-D-tryptophan


orilotimod

D-γ-glutamyl-D-tryptophane

orilotimod

D-γ-glutamyl-D-triptófano

C₁₆H₁₉N₃O₅



paritaprevirum
 paritaprevir


(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16*a*-tetradecahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14*a*(5*H*)-carboxamide

paritaprévir

(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(cyclopropylsulfonyl)-6-(5-méthylpyrazin-2-carboxamido)-5,16-dioxo-2-(phénanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16a-tétradécahydrocyclopropa[*e*]pyrrolo[1,2-*a*][1,4]diazacyclopentadécine-14*a*(5*H*)-carboxamide

paritaprevir

(2*R*,6*S*,12*Z*,13*aS*,14*aR*,16*aS*)-*N*-(ciclopropilsulfonyl)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxy)-1,2,3,6,7,8,9,10,11,13*a*,14,15,16,16a-tetradecahidroiciclopropa[*e*]pirrolo[1,2-*a*][1,4]diazaciclopentadecina-14*a*(5*H*)-carboxamida

C₄₀H₄₃N₇O₇S

pasotuxizumabum #
pasotuxizumab

immunoglobulin scFv-scFv, anti-[*Homo sapiens* FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], humanized and chimeric monoclonal antibody bispecific single chain;
scFv anti-FOLH1 (1-243) [humanized VH (*Homo sapiens*IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-mer tris(tetraglycyl-seryl) linker (122-136) -humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9](137-243)] -6-mer seryl-tetraglycyl-seryl linker (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus*IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tetraglycyl-seryl) linker (375-389) -humanized V-LAMBDA (*Homo sapiens* IGLV7-43*01(85.10%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidine (499-504)

pasotuxizumab

immunoglobuline scFv-scFv, anti-[*Homo sapiens* FOLH1 (folate hydrolase, antigène membranaire spécifique de la prostate, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticorps monoclonal humanisé et chimérique bispécifique à chaîne unique;
scFv anti-FOLH1(1-243) [VH humanisé (*Homo sapiens* IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01) [8.8.14](1-121)-15-mer tris(tétraglycyl-séryl) linker (122-136) - V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9](137-243)] -6-mer séryl-tétraglycyl-séryl linker (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus* IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01) [8.10.16] (250-374) -15-mer tris(tétraglycyl-séryl) linker (375-389) – V-LAMBDA humanisé (*Homo sapiens* IGLV7-43*01(85.00%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidine (499-504)

pasotuxizumab

inmunoglobulina scFv-scFv, anti-[*Homo sapiens* FOLH1 (folato hidrolasa, antígeno de membrana específico de la próstata, PSMA)]/anti-[*Homo sapiens* CD3E (CD3 épsilon)], anticuerpo monoclonal humanizado y quimérico biespecífico monocatenario;
IGHV3-11*01 (85.70%)-(IGHD)-IGHJ4*01 [8.8.14] (1-121) -15-mer tris(tetraglicil-seril) conector (122-136) - V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (81.10%)-IGKJ2*01Q120>G (236)) [6.3.9] (137-243)] -6-mer seril-tetraglicil-seril conector (244-249) -scFv anti-CD3E (250-498) [*Mus musculus* VH (*Mus musculus* IGHV10-1*02 (91.90%)-(IGHD)-IGHJ3*01 [8.10.16] (250-374) -15-mer tris(tetraglicil-seril) conector 375-389) -V-LAMBDA humanizado (*Homo sapiens* IGLV7-43*01(85.00%)-IGLJ3*02 [9.3.9] (390-498)] -hexahistidina (499-504)

```

QVQLVESGGG LVKPGESLRL SCAASGFTFS DYYMYWRQA PGKGLEWVAI 50
ISDGGYYTTY SDIKGRFTI SRDANKNSLY LQMNSLKAED TAVYYCARGF 100
PLLRHGAMDY WGQGTILVTVS SGGGGSGGGG SGGGGSDIQM TQSPSSLSAS 150
VGDRVITICK ASQNVDTNVA WYQKPGQAP KSLIYSASYR YSDVPSRFSG 200
SASGTDFTLT ISSVQSEDFI TYQCQQYDSY PYTFGGGTKL EIKSGGGGSE 250
VQLVESGGGL VQPGGSLKLS CAASGFTFNK YAMNWRQAP GKGLEWVARI 300
RSKYNNYATY YADSVKDRFT ISRDDSKNTA YLQMNNLKTE DTAVYYCVRH 350
GNFGNSYISY WAYWGQGLTV TVSSGGGGSG GGGSGGGGSQ TVVTQEPFLT 400
VSPGGTITLT CGSSTGAVTS GNYPNWVQK PGQAPRLIG GTKFLAPGTP 450
ARFSGSLGG KAALTLSGVQ FEDEAEYYCV LWYSNRWVFG GGTCLTVLHH 500
HHHH

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain C23 C104 22-96 159-224 271-347 411-479

patidegibum
patidegib

N-[(2*S*,3*R*,3'*R*,3*aS*,4'*aR*,6*S*,6'*aR*,6'*bS*,7*aR*,12'*aS*,12'*bS*)-3,6,11',12'*b*-tetramethyl-2',3',3*a*,4,4',4'*a*,5,5',6,6',6'*a*,6'*b*,7,7',7*a*,8',10',12',12'*a*,12'*b*-icosahydro-1'*H*,3*H*-spiro[furo[3,2-*b*]pyridine-2,9'-naphtho[2,1-*a*]azulen]-3'-yl)]methanesulfonamide


patidégeb

N-[(2*S*,3*R*,3'*R*,3*aS*,4'*aR*,6*S*,6'*aR*,6'*bS*,7*aR*,12'*aS*,12'*bS*)-3,6,11',12'*b*-tétraméthyl-2',3',3*a*,4,4',4'*a*,5,5',6,6',6'*a*,6'*b*,7,7',7*a*,8',10',12',12'*a*,12'*b*-icosahydro-1'*H*,3*H*-spiro[furo[3,2-*b*]pyridine-2,9'-naphto[2,1-*a*]azulen]-3'-yl)]méthanesulfonamide

patidegib

N-[(2*S*,3*R*,3'*R*,3*aS*,4'*aR*,6*S*,6'*aR*,6'*bS*,7*aR*,12'*aS*,12'*bS*)-3,6,11',12'*b*-tetrametil-2',3',3*a*,4,4',4'*a*,5,5',6,6',6'*a*,6'*b*,7,7',7*a*,8',10',12',12'*a*,12'*b*-icosahidro-1'*H*,3*H*-espiro[furo[3,2-*b*]piridina-2,9'-nafto[2,1-*a*]azulen]-3'-il)]metanosulfonamida

C₂₉H₄₈N₂O₃S



peficitinibum


peficitinib

4-[[[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hydroxyadamantan-2-yl]amino]-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxamide

péficitinib

4-[[[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hydroxyadamantan-2-yl]amino]-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxamide

peficitinib

4-[[[(1*R*,2*s*,3*S*,5*s*,7*s*)-5-hidroxiadamantan-2-il]amino]-1*H*-pirrolo[2,3-*b*]piridina-5-carboxamida $C_{18}H_{22}N_4O_2$ **pegargiminasum #**

pegargiminase

[111-glutamic acid,209-serine]arginine deiminase (ADI, arginine dihydrolase, AD) from *Mycoplasma hominis*, an average of five amino groups are amidified with 4-[ω-methoxypoly(oxyethylene)]-4-oxobutanoyl, produced in *Escherichia coli*

pégargiminase

[111-acide glutamique,209-sérine]arginine désiminase (ADI, arginine dihydrolase, AD) de *Mycoplasma hominis*, produite par *Escherichia coli*, et dont cinq groupes amino, en moyenne, sont amidifiés par le 4-[ω-méthoxypoly(oxyéthylène)]-4-oxobutanoyl

pegargiminasa

[111-ácido glutámico,209-seria]arginina desiminasa (ADI, arginina dihidrolasa, AD) de *Mycoplasma hominis*, producida en *Escherichia coli*, en la cual 5 grupos amino por término medio, están amidificado por 4-[ω-metoxipoli(oxiétileno)]-4-oxobutanoyl $C_{2091}H_{3276}N_{540}O_{607}S_{15} ((C_5H_8O_3(C_2H_4O)_n)_a$



Sequence / Séquence / Secuencia

```

SVFDSKFNGL HVYSEIGELE TVLVHEPGRE IDYITPARLD ELLFSAILES 50
HDARKEHQSF VKIMKDRGIN VVELTDLVAE TYDLASKAAK EEFLETFLFE 100
TVPLTEANK EAVRAFLLSK PTHMVEFMM SGITKYELGV ESENELIVDP 150
MPNLVYTRDP FASVNGVTI HEMRYIVRRR ETLFARFVER NHPKLVKTPW 200
YYDPAMKMSI EGGDVFIYNN ETLVGVGVSER TDLDTITLLA KNIKANKVEE 250
FKRIVAINVP KWTNLMHLDL WLTMLDKNKF LYSPIANDVF KFWDYDLVNG 300
GAEPQPQLNG LPLDKLLASI INKEPVLIFI GGAGATEMEI ARETNFDGTN 350
YLAIKPGLVI GYDRNEKTNA ALKAAGITVL PHGNQLSLG MGNARCMSP 400
LSRKDVKKW 408

```


Potential modified residues* / Résidus modifiables* / Restos potencialmente modificados*



* an average of 5 (a) out of 28 are pegylated / 5 (a) sur les 28 sont en moyenne pégylés / 5 (a) cada 28 por término medio están pegilados

pegvaliasa


mutéina (S 503, S 565) de la fenilalanina amoniaco-lias
de *Anabaena variabilis*, pegilada, producida en
Escherichia coli a partir de ADN recombinante:
[503,565-diserine (C>S)]fenilalanina amoniaco-liase (EC
4.3.1.24) de *Anabaena variabilis* de cuyos restos lisil 5, por
término medio, están N^6 -{6-[ω-
metoxipoli(oxietileno)]hexanoil} substituidos



Sequence / Séquence / Secuencia

MKTLSSQAQSK TSSQQFSFTG NSSANVIIGN QKLTINDVAR VARNGLTVSL 50
TNNTDILQGI QASCDYINNA VESGEPIYGV TSGFGGMANV AISREQASEL 100
QTNLVWFLKT GAGNKLPAD VRAAMLLRAN SHMRGASGIR LELIKRMEIF 150
LNAGVTPYVY EFGSIGASGD LVPLSYITGS LIGLDPSEFKV DFNGKEMDAP 200
TALRQLNLSP LTLLEKEGLA MMNGTSVMTG IAANCYVDTQ ILTAIAMGVH 250
ALDIQALNGT NQSFHPIHN SKPHPGQLWA ADQMISLLAN SQLVRDELGD 300
KHNDYRDELI QDRYSLRCLP QYLGPIVDGI SQIAKQIEIE INSVTDNPLI 350
DVDNQASYHG GNFLGQYVGM GMDHLRYIIG LLAKHLVDQI ALLASPEFSN 400
GLPPSLGNNR ERKVNMLKG LQICGNSIMP LTFYGNSTIA DRFPTHAEQF 450
NQNINSQGYT SATLARRSVD IFQNYVAIAL MFGVQAVDLR TYKKTGHYDA 500
RASLSFATER LYSAVRHVVG QKPTSDRPYI WNDNEQGLDE HIARISADIA 550
AGGVIVQAVQ DILPSLH 567

Modified residues / Résidus modifiés / Restos modificados



polmacoxibum

polmacoxib



4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-
2-yl]-benzenesulfonamide

polmacoxib

4-[3-(3-fluorophényl)-5,5-diméthyl-4-oxo-4,5-dihydrofuran-
2-yl]-benzènesulfonamide

polmacoxib

4-[3-(3-fluorofenil)-5,5-dimetil-4-oxo-4,5-dihidrofuran-2-il]-
bencenosulfonamida



presatovirum

presatovir


N-(2-[(2*S*)-2-{5-[(3*S*)-3-aminopyrrolidin-1-yl]-
6-methylpyrazolo[1,5-*a*]pyrimidin-2-yl}piperidin-
1-yl]carbonyl)-4-chlorophenyl)methanesulfonamide

présatovir

N-(2-[(2*S*)-2-{5-[(3*S*)-3-aminopyrrolidin-1-yl]-
6-méthylpyrazolo[1,5-*a*]pyrimidin-2-yl}pipéridin-
1-yl]carbonyl)-4-chlorophényl)méthanesulfonamide

presatovir

N-(2-[(2*S*)-2-{5-[(3*S*)-3-aminopirrolidin-1-il]-6-metilpirazolo[1,5-*a*]pirimidin-2-il}piperidin-1-il]carbonil)-4-clorofenil)metanosulfonamida

 $C_{24}H_{30}ClN_7O_3S$
**rabacfosadinum**

rabacfosadine


diethyl *N,N'*-[({2-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]ethoxy)methyl}phosphinylidene]bis-L-alaninate

rabacfosadine

N,N'-[({2-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]éthoxy)méthyl}phosphinylidène]bis-L-alaninate de diéthyle

rabacfosadina

N,N'-[({2-[2-amino-6-(ciclopropilamino)-9*H*-purin-9-il]etoxi}metil}fosfinilideno]bis-L-alaninato de dietilo

 $C_{21}H_{35}N_8O_6P$
**rapastinelum**

rapastinel


L-threonyl-L-prolyl-L-prolyl-L-threoninamide

rapastinel

L-thréonyl-L-prolyl-L-prolyl-L-thréoninamide

rapastinel

L-treonil-L-proil-L-proil-L-treoninamida

 $C_{18}H_{31}N_5O_6$


relenopridum
relenopride

4-amino-*N*-[1-[(3*S*)-3-[(carbamoyl)oxy]-3-(4-fluorophenyl)propyl]-piperidin-4-yl)methyl]-5-chloro-2-methoxybenzamide


rélénopride

4-amino-*N*-[1-[(3*S*)-3-[(carbamoyl)oxy]-3-(4-fluorophényl)propyl]-pipéridin-4-yl)méthyl]-5-chloro-2-méthoxybenzamide

relenoprida

4-amino-*N*-[1-[(3*S*)-3-[(carbamoi)oxi]-3-(4-fluorofenil)propil]-piperidin-4-il)metil]-5-cloro-2-metoxibenzamida

C₂₄H₃₀ClFN₄O₄



reveglucosidasum alfa #
reveglucosidase alfa

des-(2-7)-human insulin-like growth factor II fusion protein with glycyl-L-alanyl-L-prolyl-human lysosomal alpha-glucosidase (acid maltase, aglucosidase alfa) produced in Chinese hamster ovary (CHO) cells, glycoform alfa

révégucosidase alfa

dès-(2-7)-facteur II de croissance humain semblable à l'insuline, protéine de fusion avec la glycyl-L-alanyl-L-prolyl-alpha-glucosidase lysosomiale humaine (maltase acide, aglucosidase alfa), forme glycosylée alfa produite par des cellules ovariennes de hamster chinois (CHO)

reveglucosidasa alfa

des-(2-7)-factor II de crecimiento humano semejante a la insulina, proteína de fusión con la glicil-L-alanil-L-proil-alfa-glucosidasa lisosómica humana (maltasa ácida, aglucosidasa alfa), forma glicosilada alfa, producida por células ováricas de hamster chino (CHO)

C₄₇₃₅H₇₁₈₉N₁₂₆₁O₁₃₇₁S₃₈

Sequence / Séquence / Secuencia

```

ALCGGELVDT LQVGGURGF YFSRPASRVV RRSRGIVEEC CFRSCDLALL 50
ETVCAFPKAS EGAPAHGPRP RAVPTQCDVP PNRFRDCAPD KAITQEQCEA 100
RGCCYIPAKQ GLQGAQMGGP WCFPPPSYFS YKLENLSSE MGYTATLRTT 150
TPTFPPKDIL TLRLDVMEMT ENRLHFTIKD PANRREYVPL ETPHVVSRAP 200
SPLYSVEFSE EPPGVIVHRQ LDGRVLLNTT VAPLFFADQF LQLSTLSPSQ 250
YITGLAEHLN FIMLSTSWTR TILWNRDLAP TPGANLYGSH PFTLALDELGG 300
SAHGVFLNLS NAMDVVLQPS PALSWRSTGG LLDVYIFLGP EPKSVVQQYL 350
DVVGYPFMPP YWGLGFHLCR WGYSSTAITR QVVNMTTRAH FFLDVQWDL 400
DYMDSRRDFT FNKDGFRDFF AMVQELHGGG RRYMMIVDPA ISSSGFAGSY 450
RPYDEGLRRG VFITNETGQP LIGKVWFGST AFPDFTNPTA LAWWEDMAVE 500
FRDQVFFDGM WIDMNEPSNF IRGSEDCGFN NELENFPYVP GYVGGLQAA 550
TICRASHQFL STYVNLNLY GLTEAISHR ALVKARATVP FVISRFTFAG 600
HGRYAGHWGT DVNSSWEQLA SSVPEILQFN LLGVPLVGAD VCGFLGNTSE 650
ELCVRWTLQG AFYFPMRNHN SLLSLPQEPY SFSEPAQQAM RKALTLYAL 700
LPHLYTLFHQ AHVAGETVAR PLFLEFFKDS STWTVDHQLL WGEALLITPV 750
LQAGKAETVG YPFLSTWYDL QTVPEALGS LFPFAPAPRE PAIRSEGQWV 800
TLPAFLDTIN VHLRGVYIIP LQGPGLTTE SRQPMALAV ALTHGGGARG 850
ELGWDGDESL EVLERGAYTQ VIFLARNTTI VNELVRVTSE GAGLQLQKVT 900
VLGVATAPQQ VLSNGVPSN FTYSPDTKVL DICVSLLMGE QFLVSWC 947

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
3-41 15-54 40-45 77-103 87-104 98-122 528-553 642-653 933-947

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-135 Asn-228 Asn-465 Asn-487 Asn-647 Asn-877 Asn-920

revusiranum

revusiran

[(2*S*,4*R*)-1-{30-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxo-6,10-diazahexadecyl]-12,19,25-trioxo-16,30-dioxo-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen 2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroguanlyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl duplex with 2'-O-methyl-*P*-thiocytidylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyluridine

révusiran

duplex de l'hydrogène-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroguanlyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyladenylyl-(3'→5')-2'-O-méthyladenylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthyladenylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl de [(2*S*,4*R*)-1-{30-(2-acétamido-2-déoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acétamido-2-déoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxo-6,10-diazahexadécyl]-12,19,25-trioxo-16,30-dioxo-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]méthyle, avec le 2'-O-méthyl-*P*-thiocytidylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-O-méthyladenylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-O-méthylcytidylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthyladenylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-O-méthyladenylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-O-méthyladenylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorocytidylyl-(5'→3')-2'-O-méthyluridine

revusirán

dúplex del hidrógeno-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilato de [(2*S*,4*R*)-1-{30-(2-acetamido-2-desoxi-β-D-galactopiranosil)-14,14-bis[16-(2-acetamido-2-desoxi-β-D-galactopiranosil)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecil]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoil}-4-hidroxi-pirolidin-2-il]metilo, con el 2'-O-metil-*P*-tiocitidilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tiouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-O-metiluridina

C₅₁₇H₆₇₆F₂₂N₁₇₁O₃₁₄P₄₃S₂


[(3'→5') U-G-G-G-A-U-U-U-C-A-U-G-U-A-A-C-C-A-A-G-A-R1]

[(5'→3') Cs-Us-A-C-C-C-U-A-A-A-G-U-A-C-A-U-G-G-U-U-C-U]

Legend

X = 2'-deoxy-2'-fluoroX = 2'-O-methyl- = -PO₃H-

s- = -POSH-

**ribociclibum**

ribociclib


7-cyclopentyl-*N,N*-dimethyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-7*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxamide

ribociclib

7-cyclopentyl-*N,N*-diméthyl-2-[[5-(pipérazin-1-yl)pyridin-2-yl]amino]-7*H*-pyrrolo[2,3-*d*]pyrimidine-6-carboxamide

ribociclib

7-ciclopentil-*N,N*-dimetil-2-[[5-(piperazin-1-il)piridin-2-il]amino]-7*H*-pirrolo[2,3-*d*]pirimidina-6-carboxamida

$C_{23}H_{30}N_8O$ **rimiducidum**

rimiducid


1,1'-{ethane-1,2-diylbis[azanediyl(2-oxoethan-2,1-diyl)oxy-3,1-phenylene]bis[(1*R*)-3-(3,4-dimethoxyphenyl)propyl]bis[(2*S*)-1-[(2*S*)-2-(3,4,5-trimethoxyphenyl)butanoyl]-piperidine-2-carboxylate}

rimiducid

bis{(2*S*)-1-[(2*S*)-2-(3,4,5-triméthoxyphényl)butanoïl]pipéridine-2-carboxylate} de 1,1'-{éthane-1,2-diylbis[azanediyl(2-oxoéthan-2,1-diyl)oxy-3,1-phénylène]bis[(1*R*)-3-(3,4-diméthoxyphényl)propyl]}

rimiducid

bis{(2*S*)-1-[(2*S*)-2-(3,4,5-trimetoxyfenil)butanoil]piperidina-2-carboxilato} de 1,1'-{etano-1,2-diilbis[azanodiil(2-oxoetan-2,1-diil)oxi-3,1-fenileno]bis[(1*R*)-3-(3,4-dimetoxyfenil)propil]}

 $C_{78}H_{98}N_4O_{20}$ **rociletinibum**

rociletinib


N-[3-({2-[4-(4-acetyl)piperazin-1-yl]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl}amino)phenyl]prop-2-enamide

rocilétinib

N-[3-({2-[4-(4-acétylpipérazin-1-yl)-2-méthoxyanilino]-5-(trifluorométhyl)pyrimidin-4-yl}amino)phényl]prop-2-énamide

rociletinib

N-[3-({2-[4-(4-acetilpiperazin-1-il)-2-metoxianilino]-5-(trifluorometil)pirimidin-4-il}amino)fenil]prop-2-enamida

 $C_{27}H_{28}F_3N_7O_3$


rurioctocogum alfa pegolum #
rurioctocog alfa pegol

pegylated recombinant DNA derived human blood coagulation factor VIII, produced in Chinese hamster ovary (CHO cells), glycoform alfa:
human blood coagulation factor VIII (antihemophilic factor, procoagulant component)-(1-1648)-peptide associated to (1649-2332)-peptide, glycoform alfa produced in CHO cells, some of its lysine residues are *N*⁶ substituted with 4-[1,3-bis({[α-methylpoly(oxyethylene)]carbamoyl}oxy)propan-2-yloxy]butanoyl radicals

rurioctocog alfa pégol

facteur VIII de coagulation humain, produit par des cellules ovariennes de hamster chinois à partir d'ADN recombinant, pégylé, forme glycosylée alfa;
association des peptides (1-1648)- et (1649-2332)- du facteur VIII de coagulation humain (facteur antihémophilique, composé procoagulant) produite par des cellules ovariennes de hamster chinois sous forme glycosylée alfa dont quelques résidus lysine sont *N*⁶ substitués par le radical 4-[1,3-bis({[α-méthylpoly(oxyéthylène)]carbamoyl}oxy)propan-2-yloxy]butanoyle

rurioctocog alfa pegol


factor VIII de coagulación humano, producido por células ováricas de hamster chino a partir de ADN recombinante, pegilado, forma glicosilada alfa;
asociación de péptidos (1-1648)- y (1649-2332)- del factor VIII de coagulación humano (factor antihemofílico, componente procoagulante) producido por células ováricas de hamster chino en forma glicosilada alfa algunos de cuyos restos lisina están *N*⁶ substituidos por radicales 4-[1,3-bis({[α-metilpoli(oxiétileno)]carbamoi}]oxi)propan-2-iloxi]butanoilo

Heavy chain / Chaîne lourde / Cadena pesada					
ATTRYRGLGV	ELSDWIDFMQD	LGELFVDVAFR	PPRPVKGSFFP	NTSVYVKYKLT	50
VFEVFDLHFN	IAKRFPMWGS	LGGETIQAEV	YDTVTVYLNK	MASHFVLSHA	100
VGVYSWKAAE	GARYDIDQDTS	REKEDDKWV	GGSHYTVQVQ	LKHSQPMASD	150
PLCLTYSYLS	HVOLVDKQNS	GLIGALLER	EGSLAKEKTV	THKGIFFLLA	200
YVFLVYVFLV	ETKNVYVYVFL	YVFLVYVFLV	MHTVYGVKVR	YVFLVYVFLV	250
KSYVYVHGLG	CTFPEVHSIV	LEGHTFLVRN	HROQLESLSE	ITFLTAQTLT	300
MDVQYQFQM	QVHQDQHGDS	EAYVYKDSCP	EWQLQRKNM	EABEABDSDL	350
TDPSMDVYKS	DDDNQSPSIQ	IVSVAKKHEW	TFWVYIAAEE	EDWDVAPVLV	400
ADPSRDSVRS	YLVNGRPGIV	KRYKYVRFMA	YTDFTFKTRE	AIQHESGLGI	450
PLLYGEVGDIT	LILFIKNQAS	RFYNIYPHCI	TDVRFYSRR	LRPGVKHLKD	500
PIPLFELGPI	YKMTVTVDEG	PTKSIDVDEG	RYRYSFVNME	LDASGLIGP	550
LILCYKESVD	QRGNQIMSDY	RNVLSFVEND	ENRSWYLTEN	LIQFLPNAG	600
VQLEDPEFEQA	SNTMHSINSK	VFDSLSQVSC	LHEAVYVAIL	SIGAQDTFLS	650
VFFSGYFTFKH	KMYVEDTILT	FFFSFGSVEN	SMENPLGLW	GCNDSDFRNR	700
GMTALLXKHS	CKDNTDGYDE	ZYEDISAYL	LKSNNAIEPR	SPQSRRHS	750
TQKQFNATL	IPENDIEKTD	PWFHARTTMP	KQTVNVSDDL	LMLLQSPFT	800
GLGSLSDLQE	AKYETFSDDP	SPGAIDSNNS	LEIHFTHRP	LHSGDMVFT	850
PESGILQPRM	EKLGTDTAATE	LKGLDPKFSV	TSNNLTNTL	SDNLAAQTDN	900
TSSLGQPSLPE	VHYSDQSLDT	LFGKSSSLTE	ESGGSLSLSE	ENNDSKLLSE	950
GLMNSQESSW	GKNVYSSTESG	LIETKGRKHA	PALLTKDNAL	FKVSIILKLT	1000
KNTNSNATST	RHTHIDGPSL	RLNFSQSPKV	NLTSESDTEK	FVTPLIDHRM	1050
IMDKNATATL	LNHMSNKLNS	SKNMEMVQPE	KEGPIPPDAQ	NPDMSSFVKM	1100
PLFESARQIT	RTHGKNSLTS	SGKQSPKQVL	SLGPEKSEV	QNFLSEKNKV	1150
VVGKEGFETD	VGLKEMVFPFS	SRNFLFTNLD	LNHEHNTHNQ	EKKYIEBIEK	1200
KETLQIENQV	LOPHITVETN	SRNFMKNLNL	STRQNVESGY	DAQAPVLVD	1250
FRSLNDNSTN	TKKHTAHFSK	LEENESLEGL	GNQTKQVBEK	YACTRISPLN	1300
TSQNFVTVTR	SKRALQKQRL	PLETEELER	ITVDVSTQW	SKMNHKTLFP	1350
TLTQIDNYEK	EKGATIPASPL	SDCLTRSHSI	POANKRSLPI	AKVGSFSPSI	1400
PIYTVRLFRV	DNSHLPQSLP	YRKKDSRQSV	SSHFLQAKSS	NNLSLAAILT	1450
EMTQDFFPVE	SLGTSATNSV	TYKKVNTVLT	PKPDLPTSGT	KVBLPLKVHI	1500
YQKDLFRET	SPGSGPHGLD	VEGSLQYQTE	GAIKWNEANR	QKVPFFVRLA	1550
TESAKTPTSL	LLDPLADWNL	YGTOIKPEEW	KSQKSEKPEK	AFKKDKTDS	1600
LNACSNESHA	AAINEGONKP	EIEVTVATGR	RATERLCONP	VPKLKHOR	1650

Light chain / Chaîne légère / Cadena ligera				EI	1650
TRTTTQSDQW	EISDDTTSIV	EMKKEDFDIY	DEDENQSPRS	FQKKTTHRYF	1700
AAVERLDMDY	BDDSPHLVRN	RAQGSQVQF	KKVVFEQFTD	GSPTQPLYRG	1750
ELNEHLHGLK	PYTAREAEVN	IMVTFRNQAQ	RPYSFYSSIL	VSEEDQQRQA	1800
EPPKKNFVKN	EKTETVFWKV	HMAAPTDEK	DCKAAVFSV	DLDEKHVHSG	1850
LIGCLPLVCHT	TNKNPAHQGR	VTVOEQEAFI	ITFIDETKSYW	FETNMERNCS	1900
APCNICIMVED	TKFNVRFHJA	INGYIMDLTP	GLVMAQDQRI	RWLLSMGNS	1950
ENIH5SHGSE	HVPTVRKKEE	YKMALYNLYP	GVVFTEVMEPL	SKAGIWRVEC	2000
LIGELHAGM	STFLFVNSJN	CTPLQMGASG	HIRDFQTSIA	GOYQGWAPKL	2050
ARLHYSLGSL	AWSTKEPFSW	IKVDLLAPMI	IHGKTIQGTQ	QKFSSLYIQC	2100
FIMYSLDGLK	QMTQYRGNST	KLTMVFFGNP	DSSGKHNFIT	NPPIIARYIR	2150
LHPTYSYSIR	TLRMEIAGCD	LNSCSPKMLG	ESKASIDQKI	TASSVFYTFM	2200
LDWSPSKARL	HLGRSNRSGP	PQVNNPKEGM	QVDFQAFMTG	TGVTQTQGVK	2250
LSTYSMYKFE	LISSSQDQGR	WTLFVNGKGV	KVFQNGQDSF	TPVFNSLDPP	2300
LTTRYLYRHL	QSNVHQIALH	MEVLJGCEAF	LY		2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados



* potential pegylated residues / résidus pouvant être pégylés / restos potencialmente pegilados

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-41 Asn-239 Asn-582 Asn-757 Asn-784 Asn-828 Asn-900 Asn-943
 Asn-963 Asn-1001 Asn-1005 Asn-1055 Asn-1066 Asn-1185 Asn-1255
 Asn-1259 Asn-1282 Asn-1300 Asn-1412 Asn-1442 Asn-1810 Asn-2118

sarolanerum
sarolaner


1-{5'-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]-3'-*H*-spiro[azetidine-3,1'-[2]benzofuran]-1-yl]-2-(methanesulfonyl)ethanone

sarolaner

1-{5'-[(5*S*)-5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl]-3'-*H*-spiro[azétidine-3,1'-[2]benzofuran]-1-yl]-2-(méthanesulfonyl)éthanone

sarolaner

1-{5'-[(5*S*)-5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-dihidroisoxazol-3-il]-3'-*H*-espiro[azetidina-3,1'-[2]benzofuran]-1-il]-2-(metilsulfonyl)etanona

 $C_{23}H_{18}Cl_2F_4N_2O_5S$
**savolitinibum**

savolitinib


1-[(1*S*)-1-(imidazo[1,2-*a*]pyridin-6-yl)ethyl]-6-(1-methyl-1*H*-pyrazol-4-yl)-1*H*-1,2,3-triazolo[4,5-*b*]pyrazine

savolitinib

1-[(1*S*)-1-(imidazo[1,2-*a*]piridin-6-yl)éthyl]-6-(1-méthyl-1*H*-pyrazol-4-yl)-1*H*-1,2,3-triazolo[4,5-*b*]pirazine

savolitinib

1-[(1*S*)-1-(imidazo[1,2-*a*]piridin-6-il)etil]-6-(1-metil-1*H*-pirazol-4-il)-1*H*-1,2,3-triazolo[4,5-*b*]pirazina

 $C_{17}H_{15}N_9$
**sembragilinum**

sembragiline


N-[(3*S*)-1-{4-[(3-fluorophenyl)methoxy]phenyl}-5-oxopyrrolidin-3-yl]acetamide

sembragiline

N-[(3*S*)-1-{4-[(3-fluorophényl)méthoxy]phényl}-5-oxopyrrolidin-3-yl]acétamide

sembragilina

N-[(3*S*)-1-{4-[(3-fluorofenil)metoxi]fenil}-5-oxopirrolidin-3-il]acetamida

 $C_{19}H_{19}FN_2O_3$
**tenofovirum alafenamidum**

tenofovir alafenamide


propan-2-yl *N*-[(*S*)-({[(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}methyl)phenoxyphosphinoyl]-*L*-alaninate

ténofovir alafénamide

N-[*(S)*-({[(*2R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}méthyl)phénoxyphosphinoyl]-L-alaninate de propan-2-yle

tenofovir alafenamida

N-[*(S)*-({[(*2R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxi}metil)fenoxifosfinoil]-L-alaninato de propan-2-ilo

C₂₁H₂₉N₆O₅P**tepotinibum**

tepotinib


3-{1-[(3-{5-[(1-méthylpipéridin-4-yl)méthoxy]pyrimidin-2-yl}phényl)méthyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile

tépotinib

3-{1-[(3-{5-[(1-méthylpipéridin-4-yl)méthoxy]pyrimidin-2-yl}phényl)méthyl]-6-oxo-1,6-dihydropyridazin-3-yl}benzonitrile

tepotinib

3-{1-[(3-{5-[(1-metilpiperidin-4-il)metoksi]pirimidin-2-il}fenil)metil]-6-oxo-1,6-dihidropiridazin-3-il}benzonitrilo

C₂₉H₂₈N₆O₂**tradipitantum**

tradipitant


{2-[1-{[3,5-bis(trifluorométhyl)phényl]méthyl}-5-(pyridin-4-yl)-1*H*-1,2,3-triazol-4-yl]pyridin-3-yl}(2-chlorophényl)méthanone

tradipitant

{2-[1-{[3,5-bis(trifluorométhyl)phényl]méthyl}-5-(pyridin-4-yl)-1*H*-1,2,3-triazol-4-yl]pyridin-3-yl}(2-chlorophényl)méthanone

tradipitant


{2-[1-{[3,5-bis(trifluorometil)fenil]metil}-5-(piridin-4-il)-1*H*-1,2,3-triazol-4-il]piridin-3-il}(2-clorofenil)metanona

C₂₈H₁₆ClF₆N₅O**transcrocetinum**

transcrocetin

transcrocétine


transcrocetina

all-trans-8,8'-diapocartene-8,8'-dioic acidacide *tout-trans*-8,8'-diapocarotène-8,8'-dioïqueácido *todo-trans*-8,8'-diapocaroteno-8,8'-dioicoC₂₀H₂₄O₄**ulixertinibum**

ulixertinib

ulixertinib

ulixertinib

4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-*N*-[(1*S*)-1-(3-chlorophenyl)-2-hydroxyethyl]-1*H*-pyrrole-2-carboxamide4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-*N*-[(1*S*)-1-(3-chlorophényl)-2-hydroxyéthyl]-1*H*-pyrrole-2-carboxamide4-{5-cloro-2-[(propan-2-il)amino]piridin-4-il}-*N*-[(1*S*)-1-(3-clorofenil)-2-hidroxietyl]-1*H*-pirrol-2-carboxamidaC₂₁H₂₂Cl₂N₄O₂

uprosertibum

uprosertib


N-[(2*S*)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)furan-2-carboxamide

uprosertib

N-[(2*S*)-1-amino-3-(3,4-difluorophényl)propan-2-yl]-5-chloro-4-(4-chloro-1-méthyl-1*H*-pyrazol-5-yl)furan-2-carboxamide

uprosertib

N-[(2*S*)-1-amino-3-(3,4-difluorofenil)propan-2-il]-5-cloro-4-(4-cloro-1-metil-1*H*-pirazol-5-il)furan-2-carboxamida

$$\text{C}_{18}\text{H}_{16}\text{Cl}_2\text{F}_2\text{N}_4\text{O}_2$$
**vanucizumabum #**

vanucizumab

immunoglobulin recombined G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiotensinogen 2, Ang2)]/anti-*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF), humanized monoclonal antibody; gamma1 heavy chain anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) -(IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) -IGHG1*01 hinge-CH2-CH3-CHS (hinge 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfide with light chain anti-ANGPT2 (1'-213') [glutaminy-prolyl-glycyl (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -linker seryl-seryl (109'-110') -*Homo sapiens* IGHG1*01 CH1-hinge (CH1 (111'-208') -hinge (1-5) (209'-213'))]; gamma1 heavy chain anti-VEGFA (1-453) [humanized VH (*Homo sapiens* IGHV3-23*03 (76.80%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 S10>C (360), T22>W (372) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain anti-VEGFA (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (242-232":245-235":365-360")-trisdisulfide

vanucizumab

immunoglobuline recombinée G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiopoietine 2, Ang2)]/anti-*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé;

chaîne lourde gamma1 anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) - (IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) - IGHG1*01 charnière-CH2-CH3-CHS (charnière 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfure avec la chaîne légère anti-ANGPT2 (1'-213') [glutaminyl-prolyl-glycyl (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -linker séryl-séryl (109'-110') -*Homo sapiens* IGHG1*01 CH1-charnière (CH1 (111'-208') -charnière (1-5) (209'-213'))];

chaîne lourde gamma1 anti-VEGFA (1-453) [VH humanisé (*Homo sapiens* IGHV3-23*03 (76.80%) - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 S10>C (360) T22>W (372) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa anti-VEGFA (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (242-232":245-235":365-360")-trisdisulfure

vanucizumab

inmunoglobulina recombinada G1-kappa/lambda, anti-[*Homo sapiens* ANGPT2 (angiopoyetina 2, Ang2)]/anti-*Homo sapiens* VEGFA (factor de crecimiento A del endotelio vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 anti-ANGPT2 (1-463) [*Homo sapiens* VH (*Homo sapiens* IGHV1-2*02 (100.00%) - (IGHD)-IGHJ3*02) [8.8.22] (1-129) -*Homo sapiens* IGKC*01 R1.4>A (130), T1.3>S (131) (130-236) - IGHG1*01 bisagra-CH2-CH3-CHS (bisagra 6-15 (237-246), CH2 (247-356), CH3 Y5>C (365), T22>S (382), L24>A (384), Y86>V (423) (357-461), CHS (462-463)) (237-463)], (236-213')-disulfuro con la cadena ligera anti-ANGPT2 (1'-213') [glutaminil-prolil-glicil (1'-3') -*Homo sapiens* V-LAMBDA (*Homo sapiens* IGLV3-21*02 (100.00%) -IGLJ1*01) [6.3.11] (4'-108') -conector seril-seril (109'-110') -*Homo sapiens* IGHG1*01 CH1-bisagra (CH1 (111'-208') -bisagra (1-5) (209'-213'))];

cadena pesada gamma1 anti-VEGFA (1-453) [VH humanizado (*Homo sapiens* IGHV3-23*03 (76.80%) - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 S10>C (360) T22>W (372) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa anti-VEGFA (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (242-232":245-235":365-360")-trisdisulfuro

anti- ANGPT2 Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKKPGASVKV SCASGYTFT GYMHVWRQA PGQGLEWMGW 50
 INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSLRLSDD TAVYYCARSP 100
 NPYYYDSSGY YYPGAFDIWG QGTMTVTVSSA SVAAPSVFIF PPSDEQLKSG 150
 TASVYVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSYSLSSST 200
 LTLKADYK HKVYACEVTH QGLSSPVTKS FNRGECCKTH TCPPCPAPEL 250
 LGGSPVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV 300
 HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 350
 TISKAKGQPR EPQVCTLPSS RDELTKNQVS LSCAVKGFYP SDIAVEWESN 400
 GQPENNYKTT PPVLDSDGSF FLVSKLTVDK SRWQQGNVFS CSVMHEALHN 450
 HYTKKSLSL PGK 463

anti- ANGPT2 Light chain / Chaîne légère / Cadena ligera
 QPGLTQPPSV SVAPGQTARI TCGGNNGISK SVHWYQKQPG QAPVLVYDD 50
 SDRPSGIPER FSGNSNGNTA TLTISRVEAG DEADYYCQVW DSSSDHYVFG 100
 TGTKVTVLSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS 150
 WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNKKPS 200
 NTKVDKKVEP KSC 213

anti-VEGFA Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWRQA PGKGLEWVGW 50
 INTYTGEPY AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYYCAKYP 100
 HYVSSHWYF DWGQGTLLV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
 LVKDYFPEPV TVSNMNGALT SGVHTFFPAVL QSSGLYSLSL VVTVPSSSLG 200
 TQYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGSPVFLFP 250
 PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
 QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
 EPQVYTLPPC RDELTKNQVS LWCLVKGFYP SDIAVEWESN GQPENNYKTT 400
 PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTKKSLSL 450
 PGK 463

anti-VEGFA Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSAVSGDRVT ITCSASQDIS NYLNMWYQKPK GKAPKVLIIYF 50
 TSSLHSGVPS RFGSGSGSTD FTLTISSLQP EDFATYYCQQ YSTVPWTFGQ 100
 GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150
 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 156-216 277-337 383-441
 22"-96" 150"-206" 267"-327" 373"-431"

Intra-L (C23-C104) 22'-87' 137'-193'
 23'"-88'" 134'"-194'"

Inter-H-L 236-213' 226"-214"

Inter-H-H 242-232" 245-235" 365-360"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

313, 303"

varlilumabum # varlilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, tumor necrosis factor receptor superfamily member 7)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-452)[*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glycyl-seryl-seryl (450-452)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

varlilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, membre 7 de la superfamille des récepteurs du facteur de nécrose tumorale)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-452)[*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glycyl-séryl-séryl (450-452)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

varililumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* anti-CD27 (TNFRSF7, miembro 7 de la superfamilia de receptores del factor de necrosis tumoral)] anticuerpo monoclonal de *Homo sapiens*;

cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*01 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (120-449) -glicil-seril-seril (450-452)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGKSLRL SCAASGFTFS SYDMHWVRQA PGKGLEWVAV 50
 IWYDGSNKYY ADSVKGRFTI SRDMSKNTLY LQMNSLRAED TAVYYCARGS 100
 GNWGFDDYWG QGTLVTVSSA STKGPSVFLP APSKSTSGG TAALGCLVKD 150
 YFPEPVTYSW NSGALTSGVH TFPAPVLSGG LYSLSVVTV PSSSLGTQTY 200
 ICNVNKKPSN TKVDKKVEPK SCDKHTCTPP CPAPELLGGP SVFLFPPKPK 250
 DTLMISSRTP VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVN HEALHNHYTQ KSLSLSPGKG 450
 SS 452

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPFSS LSASVGRVIT TCRASQGIS RFLAWYQQRP EKAPKSLIYA 50
 ASSLQSGVFS RFGSGSGSTD FTLTISLQFP EDFATYYCQQ YNTYPRFPGQ 100
 GTKVELKRTV AAPSVEIIPP SDEQLKSGTA SVVCLLNNEY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYSLSLTLT LSKADYEKKH VYACEVTHQG 200
 LSSPFTKSPFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
 22"-96" 146"-202" 263"-323" 369"-427"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 222-214' 222"-214"
 Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 299, 299"

velpatasvirum

velpatasvir



methlyl {(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-[(2*R*)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1*H*-imidazol-4-yl)-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-*d*]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate

velpatasvir

{(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-[(2*R*)-2-[(méthoxycarbonyl)amino]-2-phénylacétyl]-4-(méthoxyméthyl)pyrrolidin-2-yl]-1*H*-imidazol-4-yl)-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-*d*]imidazol-2-yl)-5-méthylpyrrolidin-1-yl]-3-méthyl-1-oxobutan-2-yl}carbamate de méthyle

velpatasvir

{(2*S*)-1-[(2*S*,5*S*)-2-(9-{2-[(2*S*,4*S*)-1-[(2*R*)-2-[(metoxicarbonil)amino]-2-fenilacetil]-4-(metoximetil)pirrolidin-2-il]-1*H*-imidazol-4-il)-1,11-dihidro[2]benzopirano[4',3':6,7]nafto[1,2-*d*]imidazol-2-il)-5-metilpirrolidin-1-il]-3-metil-1-oxobutan-2-il}carbamato de metilo

**venetoclaxum**

venetoclax


4-(4-{{2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl}piperazin-1-yl)-*N*-[{{3-nitro-4-{{(oxan-4-yl)methyl}amino}phenyl)sulfonyl}-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide

vénétoclax

4-(4-{{2-(4-chlorophényl)-4,4-diméthylcyclohex-1-én-1-yl)méthyl}pipérazin-1-yl)-*N*-[{{3-nitro-4-{{(oxan-4-yl)méthyl}amino}phényl)sulfonyl]-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide

venetoclax

4-(4-{{2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il}metil}piperazin-1-il)-*N*-[{{3-nitro-4-{{(oxan-4-il)metil}amino}fenil)sulfonyl]-2-[(1*H*-pirrolo[2,3-*b*]piridin-5-il)oxil]benzamida

**verinuradum**

verinurad



2-[[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfonyl]-2-methylpropanoic acid

vérinurad

acide 2-[[3-(4-cyanonaphtalén-1-yl)pyridin-4-yl]sulfonyl]-2-méthylpropanoïque

verinurad

ácido 2-[[3-(4-cianonaftalen-1-il)piridin-4-il]sulfanil]-2-metilpropanoico

**vonapanitasum**

vonapanitase

recombinant DNA derived type I pancreatic elastase, produced in *Pichia pastoris*: [26-tryptophan(Arg>Trp),202-leucine(Val>Leu),225-arginine(Gln>Arg)]mature human CELA1 (chymotrypsin-like elastase family member 1, pancreatic elastase 1, elastase 1, EC 3.4.21.36) non-glycosylated

vonapanitase

élastase pancréatique de type I, produite à partir d'ADN recombinant, produite par *Pichia pastoris*: [26-tryptophane(Arg>Trp),202-leucine(Val>Leu),225-arginine(Gln>Arg)]CELA1 humaine à maturité (membre 1 de la famille des élastases analogues de la chymotrypsine, élastase 1 pancréatique, élastase 1, EC 3.4.21.36) non-glycosylée

vonapanitasa

elastasa pancreática de tipo I, producida a partir de ADN recombinante, producida por *Pichia pastoris*: [26-triptófano(Arg>Trp),202-leucina(Val>Leu),225-arginina(Gln>Arg)]CELA1 humana madura (miembro 1 de la familia de elastasas análogas a la quimotripsina, elastasa 1 pancreática, elastasa 1, EC 3.4.21.36) no glicosilada

Sequence / Séquence / Secuencia

```
VVGTEAGRN SWPSQISLQY RSGGSWYHTC GGTILRQNWV MTAAHCVDYQ 50
KTRFVVAGDH NLSQNDGTEQ YVSVQKIVVH PYWNSDNVAA GYDIALRLA 100
QSVTLNSYVQ LGVLPQEGAI LANNSPCYIT GWGKTKTNGQ LAQTLQAYL 150
PSVDYAISSS SSYWGSTVKN TMVCGAGDGV RSGCQDSDGG PLHCLVNGKY 200
SLHGVTSFVS SRGCNVSRRP TVFTRVSAYI SWINNVIASN 240
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
30-46 127-194 158-174 184-214

vorhyaluronidasum alfa #

vorhyaluronidase alfa

human hyaluronidase PH-20 (hyaluronoglucosaminidase PH-20, sperm adhesion molecule 1, EC 3.2.1.35) precursor-(36-482)-peptide (mature-(1-447)-peptide), produced in Chinese hamster ovary (CHO) DG44dhfr-cells, glycoform alfa

vorhyaluronidase alfa

hyaluronidase PH-20 humaine (hyaluronoglucosaminidase PH-20, molécule adhésive 1 du sperme, EC 3.2.1.35) précurseur-(36-482)-peptide (à maturité-(1-447)-peptide), produite par des cellules ovariennes de hamster chinois DG44dhfr-, forme glycosylée alfa

vorhialuronidasa alfa	hialuronidasa PH-20 humana (hialuronoglucosaminidasa PH-20, molécula de adhesión 1 de esperma, EC 3.2.1.35) precursor-(36-482)-péptido (maduro-(1-447)-péptido), producida por células ováricas de hamster chino DG44dhfr-, forma glicosilada alfa
	C ₂₃₂₇ H ₃₅₅₃ N ₅₈₉ O ₆₆₇ S ₂₀ (protein)
	Sequence / Séquence / Secuencia LNFRAPPVIP NVFFLAWNA PSEFCLGKFD EPLDMSLFSF IGSPRINATG 50 QGVTFYVDR LGYYFYIDSI TGVTVNGGIP QKISLQDHL D KAKKDITFFYM 100 PVDNLGMAVI DWEWRPTWA RNWPKDVYK NRSIELVQQQ NVQLSLTEAT 150 EKAKQEFKA GKDFLVEITK LGKLLRPNHL WGYLFPDCY NHHYKPGYN 200 GSCFNVEIKR NDDLSWLWNE STALYPSIYL NTQQSPVAAT LYVRNRVREA 250 IRVSKIPDAK SPLPVFAYTR IVFTDQVLKF LSQDELVYTF GETVALGASG 300 IVIWGTLSIM RSMKSCLLLD NYMETILNPY IINVTLAAKM CSQVLCQEQG 350 VCIRKNWNSS DYHLNPDNF AIQLEKGGKF TVRGKPTLED LEQFSEKFCY 400 SCYSTLSCKE KADVKTDAV DVCIADGVC I DAFLKPPMET EEPQIFY 447
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 25-316 189-203 341-352 346-400 402-408 423-429
	Glycosylation sites (N, T) / Sites de glycosylation (N, T) / Posiciones de glicosilación (N, T) Asn-47 Asn-131 Asn-200 Asn-219 Asn-333 Asn-358 Thr-440

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 57
Dénominations communes internationales proposées (DCI Rec.): Liste 57
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 57
(WHO Drug Information, Vol. 21, No. 1, 2007)

p. 60	beroctocogum alfa #	
	beroctocog alfa	<i>replace the description by the following one</i>
	béroctocog alfa	<i>remplacer la description par la suivante</i>
	beroctocog alfa	<i>sustitúyase la descripción por la siguiente</i>
		human blood-coagulation factor VIII-(1-741)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide
		combinaison du facteur VIII de coagulation humain-(1-741)-peptide avec le facteur VIII de coagulation humain-(1649-2332)-peptide
		combinación del factor VIII de coagulación humano-(1-741)-péptido con el factor VIII de coagulación humano-(1649-2332)-péptido

Recommended International Non Proprietary Names (Rec. INN): List 59
Dénominations communes internationales proposées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)


p. 74 & **beroctocogum alfa #**
 75 beroctocog alfa *replace the structure by the following one*
 beroctocog alfa *remplacer la structure par la suivante*
 beroctocog alfa *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada
 ATRRYYLGA V ELSWDYMQSD LGELPVDARF PPRVPSFPP NTSVVYKTL 50
 FVEFTDHLFN IAKPRPPWMS LLGPTIAQEV YDTVITLKN MASHPVSLHA 100
 VGVSYWKASE GAEDDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
 PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSIAKEKTQ TLHKFILLFA 200
 VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPLGICHR 250
 KSVYVHWIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
 MDLGQFLLCF HISSHQHDM EAYVKVDSQP EEPQLRMKN EEAEDVDDL 350
 TDSEMDVVRF DDDNPSFSIQ IRSAKKHPK TWVHYIAAE EDWDYAPLV 400
 APDRSVKSKQ YLNNGPQRIG RKYKVRVMA YDTEFTKTR AIQHSGLIG 450
 PLYLGEVGD TLLIIFKNQAS RPYNIYPHGI TDVRLPYSR LPKGVKHLKD 500
 FPLPGGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVME RDLASGLIGP 550
 LLLCYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDPLS 650
 VFFSGYTFKH KMVEDTLTL FFFSGETVFM SMENPGLWIL GCHNSDFRNR 700
 GMTALLKVSS CDKNTGDY~~YE~~ DS~~YE~~DISAYL LSKNNAIEPR S 741

Light chain / Chaîne légère / Cadena ligera
 E I 1650
 TRTTLQSDQE EIDYDDTISV EMKKEDFDI~~Y~~ DEDENQSPRS FQKKTRHYFI 1700
 AAVERLWDYG MSSSPHVLNR RAQSGSVQPF KKVVFQFTD GSFTQPLYRG 1750
 ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
 EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
 LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETQSWY FTENMERNCR 1900
 APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGNS 1950
 ENHSHFSG HVFTVRKKEE YKMALYNLYP GVFTVEMLP SKAGIWRVEC 2000
 LIGELHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYQWAPKL 2050
 ARLHSGSIN AWSTKEPFSW IKVDLLAPMI IHGKIQGAR QKFSSLYISQ 2100
 FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKNIF NPPIIARYIR 2150
 LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
 ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
 LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TFPVNSLDDP 2300
 LLTRYLRIRH QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-41 Asn-239 Asn-1810 Asn-2118

delete/supprimer/suprimase

C3821H5813N1003O1139S35 + C3547H5400N956O1033S35

Recommended International Non Proprietary Names (Rec. INN): List 71
Dénominations communes internationales proposées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 96 **ombitasvirum**
 ombitasvir *replace the chemical name by the following one*
 ombitasvir *remplacer le nom chimique par le suivant*
 ombitasvir *sustitúyase el nombre químico por el siguiente*

dimethyl N,N'-((2S,5S)-1-(4-*tert*-butylphenyl)pyrrolidine-2,5-diyl)bis[4,1-phenyleneazanediylicarbonyl[(2S)-pyrrolidine-2,1-diyl][(2S)-3-methyl-1-oxobutane-1,2-diyl]]biscarbamate

N,N'-([(2*S*,5*S*)-1-(4-*tert*-butylphényl)pyrrolidine-2,5-diyl]bis{4,1-phénylèneazanediylicarbonyl[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})biscarbamate de diméthyle

N,N'-([(2*S*,5*S*)-1-(4-*tert*-butilfenil)pirrolidina-2,5-diil]bis{4,1-fenilenoazanodiilcarbonil[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})biscarbamato de dimetilo

p. 98
& 99

paclitaxelum trevatidum

paclitaxel trevatide
paclitaxel trévatide
paclitaxel trevatida

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

short modified fragment of human amyloid beta A4 protein covalently linked to three molecules of paclitaxel through succinyl linkers:

N^{2.1},*N*^{6.10},*N*^{6.15}-tris(4-[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acetyloxy)-2α-(benzoyloxy)-5β,20-epoxy-1,7β-dihydroxy-9-oxotax-11-en-13α-yl]oxy}-3-oxo-1-phenylpropan-2-yl]oxy)-4-oxobutanoyl) ([318-L-threonine(P>T1),324-L-serine(C>S7),325-L-arginine(G>R8),327-L-lysine(N>K10),332-L-lysine(D>K15)] human amyloid beta A4 protein precursor-(318-336)-peptide)

fragment court et modifié de la protéine bêta A4 amyloïde humaine lié de façon covalente à trois molécules de paclitaxel par autant de succinyles :

N^{2.1},*N*^{6.10},*N*^{6.15}-tris(4-[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acétyloxy)-2α-(benzoyloxy)-5β,20-époxy-1,7β-dihydroxy-9-oxotax-11-en-13α-yl]oxy}-3-oxo-1-phénylpropan-2-yl]oxy)-4-oxobutanoyl) ([318-L-thréonine(P>T1),324-L-sérine(C>S7),325-L-arginine(G>R8),327-L-lysine(N>K10),332-L-lysine(D>K15)] précurseur de la protéine amyloïde bêta A4 humaine-(318-336)-peptide)

fragmento corto y modificado de la proteína beta A4 amiloide humana unido covalentemente a tres moléculas de paclitaxel mediante succinilos :

N^{2.1},*N*^{6.10},*N*^{6.15}-tris(4-[(1*S*,2*R*)-1-benzamido-3-{[4,10β-bis(acetiloxi)-2α-(benzoiloxi)-5β,20-epoxi-1,7β-dihidroxi-9-oxotax-11-en-13α-il]oxi}-3-oxo-1-fenilpropan-2-il]oxi)-4-oxobutanoyl) ([318-L-treonina(P>T1),324-L-serina(C>S7),325-L-arginina(G>R8),327-L-lisina(N>K10),332-L-lisina(D>K15)] precursor de la proteína amiloide beta A4 humana-(318-336)-péptido

p. 115

vedroprevirum

vedroprevir
védroprévir
vedroprevir

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

(1*R*,2*R*)-1-[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy]carbonyl]amino]-3,3-dimethylbutanoyl]-4-[(8-chloro-7-[2-(morpholin-4-yl)ethoxy]-2-[2-[(propan-2-yl)amino]-1,3-thiazol-4-yl]quinolin-4-yl)oxy]pyrrolidine-2-carboxamido)-2-ethylcyclopropane-1-carboxylic acid

acide (1*R*,2*R*)-1-[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy}carbonyl)amino]-3,3-diméthylbutanoyl]-4-[(8-chloro-7-[2-(morpholin-4-yl)éthoxy]-2-[2-[(propan-2-yl)amino]-1,3-thiazol-4-yl]quinoléin-4-yl]oxy]pyrrolidine-2-carboxamido]-2-éthylcyclopropane-1-carboxylique

ácido (1*R*,2*R*)-1-[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-il]oxi}carbonil)amino]-3,3-dimetilbutanoil]-4-[(8-cloro-7-[2-(morfolin-4-il)etoxi]-2-[2-[(propan-2-il)amino]-1,3-tiazol-4-il]quinolin-4-il]oxi]pirrolidina-2-carboxamido)-2-etilciclopropano-1-carboxílico

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>

Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.